New insights into tumor necrosis factor-alpha in cancer: distinct isoforms exert opposing effects on tumor associated myeloid cells and tumorigenesis by Ardestani, Shidrokh
NEW INSIGHTS INTO TUMOR NECROSIS FACTOR-ALPHA IN CANCER:  
DISTINCT ISOFORMS EXERT OPPOSING EFFECTS ON TUMOR 
ASSOCIATED MYELOID CELLS AND TUMORIGENESIS 
By 
Shidrokh Ardestani 
 
Dissertation 
Submitted to the Faculty of the 
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements 
for the degree of 
DOCTOR OF PHILOSOPHY 
In 
Pathology 
August, 2013 
Nashville, Tennessee 
 
Approved: 
Professor Bill Valentine 
Professor Sarki Abdulkadir 
Professor Jin Chen 
Professor Ambra Pozzi 
 
  
 
 
To my family 
And  
To all those whose right to higher education has been denied  
 
 
 
 
 
 
 
 
 
 ii
ACKNOWLEDGEMENTS 
 
“Science is but a perversion of itself unless it has as its ultimate goal the 
betterment of humanity.” 
 
— Nikola Tesla 
 
 
This work would not have been possible without the help and 
encouragement of a large number of people. First, I would like to offer a special 
thank to my mentor Dr. Pampee Young for her insight, support, and guidance. 
This experience would have been much more difficult without her encouragement 
and faith in my abilities. Each of my committee, Dr. Bill Valentine, Dr. Sarki 
Abdulkadir, Dr. Jin Chen and Dr. Ambra Pozzi, have been instrumental in my 
growth and education. I appreciate the suggestions and comments given by my 
committee which served to strengthen this work. I could have not had a 
better/more helpful committee.  
Next, I would like to acknowledge past and present members of the Young 
laboratory. Sarika, Amanda (the cool side of the lab members), Dikshya and 
Desirae (the not so cool side of the lab members), Maria and Amy, thank you all. 
I am profoundly grateful and honored for knowing you and working with each one 
of you. I have to give special thanks to Dr. Li, my second mentor, who helped me 
tremendously with my project and helped me to keep my car running for the past 
four years.    
 iii
A very special thank to my mom, my dad and my brother. I am extremely 
fortunate for such a loving and supportive family.  They believed in me and 
always found ways to make me believe in myself.  I will be in debt to them 
forever for the sacrifices they made for me so I could get a better education.  
I am truly humbled by all the beloved friends I got to know from Vanderbilt 
and outside school, who have walked with me in this voyage.  I appreciate your 
support and encouragement throughout these years in graduate school. 
Multiple organizations and individuals have been vital in supporting me 
through this journey. I would like to thank the staff of the Department of 
Pathology, the BRET/IGP office and the Vanderbilt University. This work was 
supported by funding from the IBVS training grant (5 T32HL069765), NIH (R01-
HL088424) and Veterans Affairs Merit Award. 
 
 
 
 
 
 
 
 
 iv
TABLE OF CONTENTS 
 
 
  Page  
 
DEDICATION ........................................................................................................ii 
 
ACKNOWLEDGMENTS ....................................................................................... iii 
 
LIST OF FIGURES ..............................................................................................vii 
 
LIST OF ABBREVIATIONS ..................................................................................ix 
 
Chapter 
 
I. INTRODUCTION........................................................................................... 1 
 
Tumor Microenvironment ........................................................................... 1 
Myeloid Cell Recruitment and Programming.............................................. 4 
Tumor Necrosis Factor-Alpha .................................................................... 7  
 TNF-α discovery.............................................................................. 7  
 TNF-α signal transduction ............................................................... 8 
 Biological activities of soluble TNF-α ............................................ 13 
 Biological activities of membrane TNF-α....................................... 13 
TNF-α in Cancer ...................................................................................... 15 
 TNF-α as a cancer inhibitor/promoter............................................ 15 
Summary, Statement of the Problem and Goal of the Study ................... 19 
 
II. MEMBRANE VERSUS SOLUBLE TNF-ΑLPHA ISOFORMS EXERT 
OPPOSING EFFECTS ON TUMOR GROWTH AND SURVIVAL OF  
TUMOR ASSOCIATED MYELOID CELLS.................................................. 21 
 
Introduction .............................................................................................. 21 
Materials and Methods............................................................................. 23 
Results..................................................................................................... 30  
 Membrane TNF-α isoform reduces tumor growth ......................... 30  
 Expression of mTNF-α does not affect tumor proliferation or 
vascularity ..................................................................................... 35 
 Membrane TNF-α-expressing tumors are devoid of tumor 
associated myeloid cells ............................................................... 39 
 Membrane TNF-α-derived soluble factors do not affect CD11b+ 
myeloid cell migration/recruitment................................................. 45 
 Membrane TNF-α induces cell death through apoptosis-
independent pathway .................................................................... 50 
 Membrane TNF-α-induced cell death occurs through induction of 
ROS .............................................................................................. 52 
 v
 Relative expression pattern of TNF-α/TACE correlates with   
survival probability in lung cancer patients.................................... 57 
Discussion ............................................................................................... 61 
 
III. MEMBRANE TNF-ALPHA-ACTIVATED PROGRAMMED NECROSIS IS 
MEDIATED BY CERAMIDE-INDUCED REACTIVE OXYGEN SPECIES ... 66 
 
Introduction .............................................................................................. 66 
Materials and Methods............................................................................. 68 
Results..................................................................................................... 71  
 Membrane TNF-α increases cell death ......................................... 71  
 Membrane TNF-α-induced cell death is mediated through both  
 TNFR-1 and TNFR-2.................................................................... .72 
Membrane TNF-α exerts cell cytotoxicity by increasing intracellular 
ROS production............................................................................. 75 
 Inhibition of mitochondrial respiratory chain decreases mTNF-
mediated ROS generation............................................................. 77  
  Membrane TNF-α-mediated ROS production involves ceramide 
pathway......................................................................................... 79 
Discussion ............................................................................................... 82 
  
 
IV. DISCUSSIONS AND FUTURE DIRECTIONS............................................. 86 
 
Summary ................................................................................................. 86 
Role of Ceramide in Programmed Necrotic Cell Death............................ 89 
 Ceramide as a signaling molecule ................................................ 90  
 Ceramide-mediated mitochondrial ROS and programmed  
Necrosis ........................................................................................ 90  
 TNFR-1-mediated ceramide generation........................................ 91 
Proposed Models Describing Differential Activity Between Soluble and 
Membrane TNF-α .................................................................................... 92 
 Receptor/ligand stability ................................................................ 92 
Differential receptor conformation changes induced by different 
isoforms ........................................................................................ 93 
 Inhibition of TNFR/TNF-α Endocytosis.......................................... 94 
 Clustering of TNFRs and formation of lipid rafts............................ 95 
Is mTNF-α-Activated Mitochondrial ROS Sufficient for Induction of 
Programmed Necrosis? ........................................................................... 96 
  Depletion of ROS scavengers....................................................... 97 
 Sustained JNK activation ............................................................. 98 
 Significance ........................................................................................... 100 
 
BIBLIOGRAPHY............................................................................................... 102 
 vi
LIST OF FIGURES 
 
 
Figure           Page 
 
1.    Schematic of interactions between tumor and bone marrow derived myeloid 
subtypes ........................................................................................................ 3 
 
2.    Schematic representation of membrane TNF-α cleavage by TACE .............. 9 
 
3.    A schematic overview of TNFR-1 activation and downstream signaling 
events.......................................................................................................... 12 
 
4.    Schematic diagram showing the antitumorigenic/protumorigenic effects of 
TNF-α .......................................................................................................... 18 
 
5.    Generation of membrane and soluble TNF-α-expressing cells.................... 31 
 
6.    Expression of mTNF-α/sTNF-α does not affect proliferation and viability in 
LLC cells...................................................................................................... 33 
 
7.    Expression of mTNF-α does not affect proliferation and viability in B16F10 
melanoma cells ........................................................................................... 34 
 
8.    Membrane TNF-α-expressing tumor cells demonstrate delayed tumor  
growth.......................................................................................................... 36 
 
9.    Expression of mTNF-α does not affect tumor proliferation or vascularity in 
vivo .............................................................................................................. 37 
 
10.   Expression of mTNF-α does not affect proliferation and vascularity in 
B16F10 melanoma tumors .......................................................................... 38 
 
11.   Tumor derived mTNF-α does not affect T-cell content in tumor.................. 40 
 
12.   Tumor derived mTNF-α does not affect neutrophil content in tumor........... 41 
 
13.   Membrane TNF-α-expressing tumors are devoid of ER-HR3-positive 
myeloid cells................................................................................................ 41 
 
14.   Membrane TNF-α-expressing tumors are devoid of CD11b- and F4/80-
positive myeloid cells................................................................................... 43 
 
15.   Tumor inhibitory effect of mTNF-α requires the presence of TNF-α  
receptors ..................................................................................................... 44 
 
 vii
16.   Tumor-inhibitory effects of mTNF-α requires signaling between TNF-α and 
its cognate receptors ................................................................................... 46 
 
17.    Soluble factors derived from mTNF-α do not affect the rate of CD11b+ 
myeloid cell migration compared to control ................................................. 48 
 
18.   Reduced myeloid cells in mTNF-α-expressing tumors is not due to impaired 
recruitment of circulating cells ..................................................................... 49 
 
19.   Membrane TNF-α induces cell death through apoptosis-independent 
pathway....................................................................................................... 51 
 
20.   Kinetics of NF-κB, caspase-3 and BAX/Bcl-2 activation in mTNF-α 
stimulated RAW 264.7................................................................................. 53 
 
21.   Membrane TNF-α-induced cell death occurs through induction of ROS..... 55 
 
22.   ROS level in mTNF-α treated RAW 264.7 .................................................. 56 
 
23.   Human NSCLC express various levels of membrane and soluble TNF-α...59 
 
24.   Relative expression pattern of TNF-α/TACE correlates with survival 
probability in lung cancer patients ............................................................... 60 
 
25.   Membrane TNF-α isoform effectively induces cell death ............................ 73 
 
26.   Membrane TNF-induced cell death can be mediated through both TNFR-1 
or TNFR-2 ................................................................................................... 74 
 
27.   Membrane TNF-α exerts cell cytotoxicity by increasing intracellular ROS 
production.................................................................................................... 76 
 
28.   Inhibition of mitochondrial respiratory chain decreases mTNF-α-mediated 
ROS generation........................................................................................... 78 
 
29.   Schematic diagram of TNF-α-activated pathways leading to ROS  
generation ................................................................................................... 80 
 
30.    Membrane TNF-α-mediated ROS production involves ceramide pathway 81 
 
31.    Schematic overview of tumor-derived soluble and membrane TNF-α effects 
on tumor associated myeloid cells…………………………………………….88 
 
32.   Propose mechanism of mTNF-α activated ceramide pathway and 
mitochondrical ROS generation................................................................... 99 
 
 viii
List of Abbreviations 
 
 
ADAM-17  A disintegrin and metalloprotease domain 
A-SMase   Acid sphingomyelinases 
BM  Bone marrow 
Btk  Bruton’s tyrosine kinase 
CAPK  Ceramide-activated protein kinase  
CFSE  5-(and -6)-carboxyfluorescein diacetate succinimidyl ester 
CHO  Chinese hamster ovary 
cIAP  Cellular inhibitor of apoptosis  
CM  Conditioned media  
CYLD  Cylindromatosis 
DAPI  4',6-diamidino-2-phenylindole 
DC  Dendritic cells 
DD  Death domain 
DISC   Death inducing signaling complex 
DMAP  4-Dimethylaminopyridine 
DPI  Diphenyleneiodonium  
ECM  Extracellular matrix 
ELISA  Enzyme-linked immunosorbent assay  
EMA  Enriched membrane antigen 
Etk  Endothelial/epithelial tyrosine kinase 
FADD  FAS-associated protein with death domain 
FAN   Factor associated with N-SMase activation 
GLUD1  Glutamate dehydrogenase 1 
GLUL  Glutamine synthase 
HUVECs  Human umbilical vein endothelial cells 
JNK  c-Jun NH2-terminal kinase  
LDH  Lactate dehydrogenase 
LLC  Lewis lung carcinoma 
MDSC  Myeloid derived suppressor cells 
MMP  Matrix metalloproteinases 
MTT  (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NAC  N-acetylcysteine 
NADPH   Nicotinamide adenine dinucleotide phosphate-oxidase 
NF-κB  Nuclear factor-κB 
NK  Natural Killer 
NOX  NADPH oxidase 
NSCLC  Non-small-cell lung carcinoma 
NSD  Neutral sphingomyelinase domain  
N-SMase   Neutral SMase  
PECAM-1  Platelet/endothelial cell adhesion molecule-1 
 ix
 x
PLAD  Preligand binding assembly domains 
PYGL  Glycogen phosphorylase  
RIP-1  Receptor-Interacting Protein-1 
RIPA  Radio-immunoprecipitation assay 
ROS  Reactive oxygen species 
SDS  Sodium dodecyl sulfate 
SMase  Sphinglomylinase 
TAB  Transforming growth factor-β-activated kinas binding protein 
TACE  Tumor necrosis factor-alpha converting enzyme 
TAK-1  Transforming growth factor-β-activated kinase 
TAM  Tumor associated macrophages 
TEM  Tie2 expressing monocytes 
TLR  Toll-like receptor 
TNF-α  Tumor necrosis factor-alpha 
TNFR  TNF receptor 
TNFR-DKO  TNF receptor double knockout 
TRADD  Tumor necrosis factor receptor type 1-associated death domain 
TRAF  TNF receptor associated factors 
TRAIL-R1/2   TNF-related apoptosis-inducing ligand receptor-1 and -2 
TTFA  Thenoyltrifluoroacetone 
VEGF  Vascular endothelial growth factor  
TAM  Tumor associated macrohpahges 
MAPK  Mitogen-activated protein kinases 
   
   
   
 
 
 
 
CHAPTER I 
 
INTRODUCTION 
 
Tumor Microenvironment 
Tumor cells actively interact with each other and the surrounding 
interstitial tissue through cell-to-cell contacts and by both releasing and 
responding to soluble factors present in the tumor microenvironment. This 
interaction results in the generation of a population of non-malignant cells, 
collectively known as the “tumor stroma”, that are uniquely primed to support 
growth and metastasis of the malignant population (Goldoni and Iozzo, 2008; 
Whiteside, 2008). This “tumor-educated” stroma thus exhibits a unique 
phenotype that promotes the growth, invasion and metastasis of the malignant 
population (Joyce and Pollard, 2009; Pollard, 2008). 
In recent years increasing attention has been focused on the role of the 
host inflammatory cells in the stroma (Balkwill et al., 2005). The first connection 
between inflammation and cancer was made in 1863 by Rudolf Virchow, who 
noted the presence of leukocytes in neoplastic tissues (Virchow, 1963). Decades 
of extensive in vitro and in vivo studies have led to a better understanding of the 
importance of inflammatory cells in tumor formation and progression, and have 
highlighted the significance of Virchow’s discovery. Both lymphocytes and 
leukocytes have been shown to contribute to tumor inflammation. Myeloid cells 
however, are the major component of the inflammatory infiltrate frequently seen 
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in primary tumors (Balkwill and Coussens, 2004; Balkwill and Mantovani, 2001; 
Murdoch et al., 2008).  
Myeloid/macrophage cells play a key role in the immune response by 
presenting antigens to lymphocytes to start the recognition and immune inductive 
processes or by releasing regulatory molecules to stimulate lymphocyte functions 
(Mosser and Edwards, 2008). As a component of the innate immune response, 
myeloid cells activate dendritic cells and natural killer (NK) cells that can initiate 
an anti-tumor response. Consistent with this role, in some mouse experimental 
models, syngeneic macrophages from tumor bearing mice inhibited more 
melanoma growth in nude mice than control macrophages (Adelman et al., 
1983). However, often in both mouse models and in patients, the myeloid 
population can instead drive tumor progression by promoting neovascularization, 
metastasis, and immunosuppression (Balkwill and Coussens, 2004; Murdoch et 
al., 2008; Pollard, 2008).  This is achieved through various myeloid 
subpopulations, including tumor associated macrophages (TAM, M1/M2 
subtypes), myeloid derived suppressor cells (MDSC), Tie2 expressing 
monocytes (TEM), vascular leukocytes and dendritic cells (Figure 1). Identifying 
signals that contribute to the generation of these protumorigenic myeloid 
populations and their link to cancer progression has been the subject of many 
studies. Based on in vitro studies it has been hypothesized that a complex 
network of pro-inflammatory mediators is probably involved (Balkwill, 2004a; 
Coussens and Werb, 2002). Tumor cells depend on these cytokines for both 
proliferation and reprogramming cells present in the tumor  
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 Figure 1. Schematic of interactions between tumor and bone marrow 
derived myeloid subtypes. Recruitment of diverse bone marrow-derived cell 
populations to the tumor microenvironment and their effects on tumor 
progression. Tumor and stromal cells mobilize various subpopulations of tumor 
promoting bone marrow-derived cells to the peripheral blood through secretion of 
cytokines and chemokines. Diverse chemoattractant factors promote the 
recruitment and infiltration of these cells to the tumor microenvironment where 
they suppress the antitumor immunity or promote tumor angiogenesis and 
vasculogenesis. In addition cytokines produced in the tumor microenvironment 
can give rise to macrophages with distinct physiologies. This population includes 
tumor associated macrophages-M1 (TAM/M1) and TAM/M2, Tie2 expressing 
monocytes (TEMs), myeloid derived suppressor cells (MDSCs) and 
myeloid/endothelial biphenotypic vascular leukocytes.  
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microenvironment toward a protumorigenic phenotype. The Nuclear factor-κB 
(NF-κB) pathway has emerged as a key regulator of the release of these pro-
inflammatory cytokines, and is an important mediator of tumor proliferation and 
survival (Balkwill and Coussens, 2004).  It has been proposed that NF-κB 
activates signaling pathways in both cancer cells and tumor-associated 
inflammatory cells, and regulates the pro-inflammatory mediator TNF-α and other 
pro-inflammatory cytokines, thus promoting malignancy (Pikarsky et al., 2004). 
In the following section, we will provide an overview of the signaling 
molecules, cytokines and growth factors, which modulate the recruitment and 
differentiation of inflammatory cells. Furthermore, we will discuss the role of TNF-
α, an interesting example of one of the cytokines present in tumor 
microenvironment that allows tumor invasion of the host inflammatory response, 
to promote its survival and progression. 
 
Myeloid Cell Recruitment and Programming  
Circulating blood monocytes are recruited to the tumor by a range of 
growth factors and chemokines, often produced by the tumors themselves 
(Murdoch et al., 2004).  Other inflammatory cells, such as B lymphocytes, have 
been implicated in producing trophic factors that promote macrophage 
recruitment (de Visser et al., 2005). Following recruitment, it is widely accepted 
that the tumor/myeloid cell crosstalk drive recruited myeloid cells towards a 
tumor-promoting phenotype(s) (Balkwill et al., 2005; Pollard, 2004). 
Understanding the mechanisms by which pro-tumorigenic, myeloid 
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immunophenotypes are generated either in circulation or within the tumor milieu 
can be used to develop novel anti-tumor therapy. Hence, this area of study is at 
the forefront of cancer research.  While a number of factors have been identified 
that recruit myeloid cells to tumor sites (Schmid and Varner, 2007), much less is 
known about tumor-derived signals that modulate the generation of unique 
myeloid subtypes during cancer growth.  
Multiple reports have shown that tumor-derived factors contribute to bone 
marrow-derived myeloid recruitment and differentiation. A number of monocytes, 
chemoattractants and cytokines initiate recruitment of these cells to the tumor. 
Once recruited, additional tumor-derived factors, differentiate myeloid cells into 
tumor promoting cells.  These tumor-associated myeloid derived cells promote 
cancer progression through several mechanisms, including promoting 
angiogenesis, inducing tumor growth and enhancing tumor cell migration and 
invasion. Several studies have demonstrated the association between increased 
tumor vascularity and macrophage infiltration in several human cancers (Conejo-
Garcia et al., 2005; Li et al., 2009).  Macrophage infiltration has been shown to 
correlate with vessel density in endometrial, ovarian, breast and central nervous 
system malignancies. Other unique myeloid populations, such as TEMs and 
MDSCs, are thought to be present in the circulation and are recruited to the 
tumor site (Bray et al., 1993; De Palma et al., 2005; Serafini et al., 2006).  
Multiple studies have described a role for TNF-α in modulating the 
interactions between tumor cells and macrophages that result, in both increased 
invasive capacity of malignant cells, and the switch of macrophages to a tumor 
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promoting phenotype (Li et al., 2009; Pollard, 2004). TNF-α is not normally 
detected in the plasma or serum of healthy individuals but has been detected in 
the malignant and/or stromal cells in human ovarian, breast, prostate, bladder, 
and colorectal cancer, often in association with IL-1, IL-6 and macrophage colony 
stimulating factor (Bozcuk et al., 2004; Burke et al., 1996; Ferrajoli et al., 2002; 
Michalaki et al., 2004; Naylor et al., 1993; Pfitzenmaier et al., 2003). In epithelial 
ovarian cancer, TNF-α mRNA is found in epithelial tumor islands and is positively 
correlated with tumor grade (Naylor et al., 1993). There is substantial evidence 
that TNF-α is involved in the promotion and progression of cancer by regulating 
pathways that lead to cell proliferation, survival and angiogenesis (Balkwill, 
2006).  High doses of TNF-α can cause hemorrhagic necrosis through the 
destruction of tumor blood vessel and the generation of T-cell anti-tumor 
immunity (Balkwill, 2009). However, when chronically produced this cytokine may 
act as an endogenous tumor promoter, contributing to the tissue remodeling and 
stromal development that is necessary for tumor growth and progression. An 
example of this is TNF-α’s role in the generation of vascular leukocytes.  
Vascular leukocytes are a subpopulation of tumor-associated myeloid 
cells that express both endothelial and myeloid markers (Rehman et al., 2003; 
Romagnani et al., 2005; Sharpe et al., 2006). Although rare in the peripheral 
blood, vascular leukocytes are primarily associated with tumors where they 
enhance tumor growth and angiogenesis and decrease tumor necrosis. These 
myeloid/endothelial biphenotypic populations result from the endothelial 
 6
differentiation of myeloid progenitors, a process regulated by low levels of TNF-α 
expression in tumor cells. 
In the following sections our focus will turn to TNF-α as one of the 
proinflammatory cytokines present in tumor environment. The role of this tumor-
derived cytokine, which can destroy blood vessels and induced cell death at high 
concentration but can also induce angiogenic factors and tumor survival, will be 
discussed in the context of tumor biology.    
 
Tumor Necrosis Factor-Alpha 
 
The discovery of TNF-α  
TNF-α was discovered in 1892 when William Coley’s mixed bacterial toxin 
treatment cured a patient with sarcoma (Coley, 1991). Coley noted that when 
cancer patients developed certain bacterial infections, the tumors become 
necrotic. In the hope of finding a cure for cancer, Coley began to inject cancer 
patients with supernatants derived from various bacterial cultures. These cultured 
supernatants, called “Coley’s toxins”, induced hemorrhagic necrosis in tumors 
but also had undesirable side effects. This observation led to the conclusion that 
there is a factor derived from bacterial toxin that causes tumor necrosis, 
henceforth known as “tumor necrosis factor”. Later on, it was discovered that 
tumor necrosis factor is found in the serum of infected endotoxin-treated animals 
and also caused tumor regression. In 1975, Carswell et al. reported that the 
active component of Coley’s toxin was a lipopolysaccharide (endotoxin) 
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component of the bacterial cell wall. It was concluded that the necrotic factor was 
made by host cells in response to endotoxin and was not directly derived from 
bacteria. They identified macrophages as the source of tumor necrosis factor 
(Carswell et al., 1975).   
 
TNF-α signal transduction  
The TNF-α super family is a group of cytokines with important functions in 
immunity, inflammation, differentiation, control of cell proliferation and apoptosis. 
TNF family members exert their biological effects through the TNF (TNFR) 
superfamily of cell surface receptors that share a stretch of ~ 80 amino acids 
within their cytoplasmic region and the death domain (DD) that is critical for 
recruiting the death machinery. TNF-α is the founding member of the 19 different 
proteins that have so far been identified within this family. TNF-α is a 26 kDa type 
II transmembrane protein with an intracellular amino terminus. It can be cleaved 
by TNF-α-converting enzyme (TACE) into a 17 kDa soluble cytokine that is 
released into the extracellular space (McGowan et al., 2008) (Figure 2).  
TNF-α signals through two receptors: TNF receptor type 1 (TNFR-1), which is 
found in most cells in the body, and TNF receptor type 2 (TNFR-2), which is 
mainly expressed on hematopoietic cells (Grell, 1995). TNF-α can activate 
pathways leading to three different cellular responses: cell survival and 
proliferation, transcription of pro-inflammatory genes, and cell death (Waters et 
al., 2013b).  
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Figure 2. Schematic representation of membrane TNF-α cleavage by TACE 
into soluble TNF-α. TNF-α is produced as a 26 kDa membrane-associated 
protein, which is cleaved and released as a soluble 17 kDa protein by specific 
metalloproteinases, such as TNF-α-converting enzyme (TACE). TACE the major 
convertase for precursor TNF-α, processes the 78-kd homotrimeric membrane 
bound TNF-α to generate the 51-kd homotrimeric soluble TNF-α.  
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Both TNF receptors are capable of binding intracellular adaptor proteins 
that activate complex intracellular signaling processes and mediate the 
pleiotropic effects of TNF-α. Downstream signaling targets of TNFR-1 are 
activation of pro-survival/differentiation pathways (NF-κB or MAPK) or activation 
of apoptotic pathways (caspases-8,2,1).  TNFR-2 lacks the death domain but can 
affect NF-κB and JNK signaling (Baud and Karin, 2001). In vitro studies suggest 
that TNF-α preferentially binds to the ubiquitously expressed TNFR-1 whereas 
mTNF-α is the primary activating ligand for TNFR-2, expressed mostly in 
endothelial and hematopoietic cells (including myeloid cells)(Grell, 1995). 
Upon activation, TNFR-1 undergoes a conformational change in its 
cytoplasmic portion allowing it to interact with the death domain (DD) region of 
receptor interacting protein (RIP)-1, TNFR-associated death domain (TRADD), 
and TNFR-associated factor (TRAF)-2 and -5. They in turn recruit the cellular 
inhibitor of apoptosis (cIAP) forming the complex I. cIAP inhibits caspase-3 
activation and allows ubiquitinylation of RIP-1. Next, transforming growth factor-
β-activated kinase (TAK)-1/TAK-1 binding protein (TAB)-2/TAB-3 forms a 
complex that binds to ubiquitin residues on RIP-1 and activates NF-κB. 
Deubiquitinylation of RIP-1 by the enzyme cylindromatosis (CYLD), favors the 
transformation of complex I to complex II binding to the internalized death-
inducing-signaling-complex (DISC, formed by FAS-associated protein with death 
domain (FADD) and procaspase-8 (Pro-C8)) and RIP-3 (Complex II) that can 
trigger cell death through apoptosis (Micheau and Tschopp, 2003). RIP-1 
activates caspase-8 (C8) which cleaves RIP-1 and RIP-3 and induces apoptosis 
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via intrinsic (release of cytochrome C from mitochondrial) or extrinsic pathways 
resulting in caspase-3 activation. Preservation of RIP-1 kinase activity and 
autophosphorylation between RIP-1 with RIP-3 leads to the formation of 
necrosome. Necrosome induces reactive oxygen species (ROS) production via 
activation of NOX-1 at the cellular membrane or exerts direct effects in the 
mitochondria (Figure 3). The signaling pathways initiated by TNFR-2, which may 
be the preferential receptor for transmembrane TNF-α, are less characterized 
compared to those of TNF-R1. However, TNFR-2 shares some pathways similar 
to TNF-R1. In some cell types, TNFR-2 can initiate phosphorylation of IKK 
leading to nuclear translocation of NF-κB through a pathway similar to TNFR-1. 
Distinct TNFR-2 signal transduction pathways have also been described (Wajant 
et al., 2003; Waters et al., 2013a). Specifically TNFR-2 can activate 
endothelial/epithelial tyrosine kinase (Etk), a member of the Bruton’s tyrosine 
kinase (Btk) non-receptor tyrosine kinase family implicated in cell adhesion, 
migration, proliferation, and survival (Pan et al., 2002). It has also been observed 
that TNFR-2 can potentiate the apoptotic response to TNF-α (Declercq et al., 
1998; Haridas et al., 1998; Vandenabeele et al., 1995). This phenomenon has 
been explained by the “ligand-passing” model which suggests that TNFR-2 
merely serves as a membrane-bound high-affinity trap of TNF-α that delivers the 
ligand to TNFR-1 (Weiss et al., 1997).  
 
 
 
 11
 
Figure 3. A schematic overview of TNFR-1 activation and downstream 
signaling events.  Following TNF receptor activation by TNF-α, TNFR 
undergoes a conformational modification of its cytoplasmic portion allowing the 
interaction with receptor interacting protein (RIP)-1 with the death domain (DD), 
TNFR-associated death domain (TRADD), and TNFR-associated factor (TRAF). 
They in turn recruit the cellular inhibitor of apoptosis (cIAP) forming the complex 
I. cIAP inhibits caspase-3 activation and allows ubiquitylation of RIP-1. Next, 
transforming growth factor-β-activated kinase (TAK)-1/TAK-1 binding protein 
(TAB)-2/TAB-3 form a complex that binds to ubiquitin residues on RIP-1 and 
activates nuclear factor-κB (NFκB). This may occur via a p38 mitogen-activated-
protein-kinase-(p38-MAPK-) dependent pathway. Deubiquitylation of RIP-1 by 
the enzyme cylindromatosis (CYLD) favors the transformation of complex I to 
complex II binding to the internalized death-inducing-signaling-complex (DISC, 
formed by FAS-associated protein with death domain (FADD) and procaspase-8 
(Pro-C8)) and RIP-3 (Complex II). If energy is only partially insufficient, receptor 
interacting protein-1 (RIP-1) activates caspase-8 (C8) signaling for classical 
apoptosis. In this setting, caspase-8 cleaves RIP-1 and RIP-3 preserving signal 
for apoptosis; however, if caspase activity declines or prohibited 
autophosphorylation between RIP-1 with RIP-3 result in formation of the 
necrosome. Necrosome induces reactive oxygen species (ROS) production via 
activation of NOX 1 at the cellular membrane or direct effects in the 
mitochondria.  
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Biological activities of soluble TNF-α  
Soluble TNF-α (sTNF-α) was originally described as a circulating factor 
that can induce hemorrhagic necrosis of tumors. Subsequently sTNF-α was 
found to mediate widespread systemic effects. It is well known for its role as a 
major proinflammatory mediator responsible for activating the immune system 
after an infection. Bacterial pathogens and many other stimuli induce TNF-α 
production through Toll-like receptors (TLRs) and NFĸ-B signaling (Locksley et 
al., 2001; Tracey et al., 2008). Following the activation of a complex biological 
cascade involving chemokines, cytokines and endothelial adhesions, TNF-α 
along with other proinflammatory factors recruits and activates neutrophils, 
macrophages and lymphocytes at the  sites of damage and infection (Sethi et al., 
2008). 
It is crucial that TNF-α is produced in the right place, at the right time and 
in the appropriate context. Unregulated production of TNF-α can cause chronic 
inflammation, septic shock and autoimmune diseases such as Crohn's disease 
(van Deventer, 1999), psoriasis (Mease et al., 2000), severe chronic asthma 
(Berry et al., 2006) and psoriatic arthritis (Tracey et al., 2008).  
 
Biological activities of membrane TNF-α 
The role of membrane TNF-α is less understood. Upon its discovery, it 
was thought that only the soluble form of TNF-α is biologically active. However, 
subsequent studies found that the membrane form of TNF-α also possessed 
biological activities (Perez et al., 1990; Xin et al., 2006; Yang Lin, 2007). 
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Membrane TNF-activated TNFR on target cells exerts various biological 
functions that contribute to the physiological as well as pathological responses in 
health and diseases. In endothelial cells, mTNF-α induces production of pro-
coagulant agents, adhesion molecules and pro-inflammatory cytokines. Human 
umbilical vein endothelial cells (HUVECs) co-cultured with transmembrane TNF-
α-expressing Chinese hamster ovary (CHO) cells expressed tissue factors with 
synergistic actions of both TNFR-1 and -2 in an adhesion molecule (E-
selectin/ICAM-1)-dependent manner (Grell et al., 1995; Schmid et al., 1995). 
Membrane TNF-α is an important mediator for crosstalk between NK cells and 
dendritic cells (DC) (Xu et al., 2007). In mouse, proliferation and cytotoxic activity 
of NK cells were enhanced by membrane TNF-α on DCs through NK cell-surface 
TNFR-2. Expression of membrane TNF-α on adipocytes resulted in inhibition of 
differentiation by selectively activating TNFR-1 (Xu et al., 2007). In addition, 
patients with HIV infection and acute respiratory distress syndrome have 
functional and cytotoxic membrane TNF-α expression in the alveolar 
macrophages (Agostini et al., 1995; Armstrong et al., 2000), which is believed to 
be a mechanism for TNF-α-mediated lung injury.  
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TNF-α in Cancer 
 
TNF-α as a cancer inhibitor/promoter 
The mechanisms by which TNF-α exerts antitumor effects have been 
studied extensively. TNF-α inhibits tumor-induced vascularization by damaging 
the tumor-associated vasculature. It blocks blood flow and causes ischaemia of 
the tumor cells (Watanabe et al., 1988a). TNF-α also induces antitumor 
inflammatory responses through activation of NK cells and CD8 T cells (Prevost-
Blondel et al., 2000). Furthermore, TNF-α can have a direct effect on tumor cells 
by increasing lysozymal enzymes and hydroxyl radicals, and inducing 
cytochrome c release from the mitochondria and apoptosis (Watanabe et al., 
1988b) (Figure 4a). Although high doses of TNF-α have antitumor activity, there 
is growing data to suggest that endogenous TNF-α acts as a tumor promoter.  
The first published data that linked TNF-α to cancer reported that 
treatment with TNF-α induced production of more TNF-α in breast cancer cell 
lines (Spriggs et al., 1987).  Following this discovery, multiple studies have 
demonstrated that TNF-α is not only produced by inflammatory cells within the 
tumor, but many human cancer cells constitutively produce small amounts of 
TNF-α as well, and that TNF-α has a significant pro-tumerigenic role (Beissert et 
al., 1989; Naylor et al., 1990; Naylor et al., 1993; Szlosarek et al., 2006). Both in 
vivo mouse model studies and data from cancer patients suggest a significant 
role for TNF-α in tumor promotion. In mouse models, deletion or inhibition of 
TNF-α reduces the incidence of cancer and even induces resistance to 
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chemically induced carcinogenesis of the skin (Arnott et al., 2004; Moore et al., 
1999). Furthermore, in a mouse model of liver cancer induced by spontaneous 
cholangitis, inhibition of stromal cell TNF-α production decreased the incidence of 
liver tumors (Pikarsky et al., 2004).  
Direct evidence for the involvement of TNF-α in cancer comes from 
observations that TNF-α knockout mice on 4 different genetic backgrounds were 
10-fold more resistant to chemical carcinogenesis of the skin (Arnott et al., 2002; 
Arnott et al., 2004; Scott et al., 2003). Mice deficient in TNFR-1 and TNFR-2 also 
were resistance to skin cancers (Arnott et al., 2004) and TNFR-1-/- mice showed 
reduced liver tumorigenesis and liver metastasis (Kitakata et al., 2002). In 
addition, knockdown of TNF-α in ovarian cancer cell lines led to diminished 
growth and vascular density (Kulbe et al., 2007).  
Tumor cells expressing low (picogram) quantities of sTNF-α induce tumor 
growth in mouse models by recruiting myeloid cells and educating them to 
demonstrate a tumor-promoting phenotype (Li et al., 2009; Pollard, 2004). 
Absence of TNF-α signaling in TNF-α receptor deficient mice (TNFR-KO) results 
in abolishment of TNF-α-induced tumor growth and overall reduction of tumor 
associated myeloid cells. Subsequent studies did not show a decrease in the rate 
of proliferation or apoptosis in these TNF-α-expressing tumor cells (Kulbe et al., 
2007; Li et al., 2009). Endogenous TNF-α production by cancer cells positively 
correlates with increased expression of cytokines and chemokines such as 
CXCL12, CCL8, VEGF, matrix metalloproteinases (MMPs) as well as TNF-α 
itself, leading to neovascularisation, angiogenesis and metastasis (Balkwill, 
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2004b; Nabors et al., 2003).  TNF-α production via the NF- ĸB pathway in tumor 
cells is also central to the induction of cell survival and proliferation of malignant 
cells (Pikarsky et al., 2004) (Figure 4b).  
Once the protumorigenic properties of TNF-α were discovered, targeting 
TNF-α activity seemed to be a promising step toward tumor therapy. Several 
Phase I/II clinical trials have been undertaken with TNF-α antagonists in cancer 
patients (Brown et al., 2008; Harrison et al., 2007; Madhusudan et al., 2004). In 
these clinical trials, TNF-α antagonist treatment resulted in a period of disease 
stabilization in 20% of patients with advanced cancer.  Based on a few other 
trials however, anti-TNF-α therapy has been found to potentially promote skin 
cancer (Mercer et al., 2012) and lymphoma (Keystone et al., 2004) and even 
increase thrombotic events (Lee et al., 2009). Collectively, these data 
demonstrate the complex contradictory role of TNF-α and its large spectrum of 
activities, including both antitumorigenic and protumorigenic functions.  
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 Figure 4. Schematic diagram showing the antitumorigenic/protumorigenic
effects of TNF-α. (a) TNF-α causes hemorrhagic necrosis in vivo through the 
destruction of tumor vasculature. It also promotes tumor lysis by activating
tumor immune responses and can lead to direct tumour lysis via hydroxyl 
radicals and lysosomal enzymes. TNF-α can act synergistically with
 
 anti-
 a variety of 
d myeloid cells towards a protumorigenic phenotype (i.e. 
ascular leukocytes). 
 
 
 
 
 
other cytokines to activate anti-tumor immune response by T-cells. 
(b) TNF-α can induce cancer by inducing tumor proliferation and tumor 
metastasis through remodeling of the extracellular matrix (ECM) as well as 
driving tumor associate
v
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Summary, Statement of the Problem and Goal of the Study 
Myeloid cells, a heterogeneous population of bone marrow-derived cells, 
play a critical role during growth and metastasis of malignant tumors. The tumor 
promoting property of myeloid cells is induced by the production of proangiogenic 
and immunosuppressive factors at the tumor site. It is widely believed that the 
generation of the pro-tumorigenic phenotype of myeloid cells results from cross-
talk between myeloid cells and tumor cells. TNF-α has been identified as an 
important tumor-derived factor that educates tumor associated myeloid cells 
towards a protumorigenic subtype, and orchestrates the interplay between 
malignant cells and myeloid cells, which have been linked to tumor growth and 
metastasis.  
TNF-α has been shown to promote both the death and survival of tumor 
cells under different circumstances. TNF-α has also been identified as a key 
regulator of the immune and inflammatory responses to cancer. Whether TNF-α 
primarily acts in a cell autonomous manner to promote cell survival and growth or 
through paracrine interactions with the tumor stroma is unclear. 
The majority of studies that focus on the role of TNF-α in cancer biology 
have been mainly in the context of soluble TNF-α. As described in previous 
sections, TNF-α is initially expressed as a membrane bound protein with various 
biological functions. However, our knowledge of membrane TNF-α’s role in 
modulating tumor inflammatory cells and its effect on tumor growth is limited.  
There have been very few studies that suggest membrane TNF-α has a 
role in tumor biology. Monocytes primed with cytokines demonstrated increased 
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apoptosis of tumor cell lines as well as primary acute myeloid leukaemia blasts 
through a mechanism dependent on transmembrane TNF-α (Williams et al., 
2000). Monocytes (effector cells) that express either sTNF-α or only the mTNF-α 
and incubated with TNF-α-sensitive tumor cells (target cells), resulted in target 
cell death, albeit through different mechanisms, as assessed by a target cell 
cytokine profile (Yang Lin, 2007). In a study by Perez et al., myeloid-derived 
mTNF-α was demonstrated to possess an ability to kill sTNF-α resistant liver 
cancer cells by inducing apoptosis (Perez et al., 1990). 
These reports suggest that mTNF-α and sTNF-α have distinct effects on 
tumor biology which may explain the contradictory nature of current findings on 
the role of TNF-α in tumor growth and promotion. This underscores the 
importance of delineating the roles of TNF-α isoforms in tumor progression. 
The goal of this study is to understand the cellular and molecular 
differences between mTNF-α- and sTNF-α-expressing tumor cells and their roles 
in modulating host derived myeloid cells and their functions. Our proposed 
project may aid in understanding the mechanisms of mTNF-α and sTNF-α 
regulation, which could give insights into the prognosis in cancer patients and 
provide a key therapeutic approach in cancer treatment. The next chapter will 
include an in-depth discussion of the effects of tumor derived membrane and 
soluble TNF-α on tumor growth and inflammation. In chapter III, the molecular 
mechanisms that distinguish membrane TNF-α from the soluble form will be 
evaluated.  
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CHAPTER II 
 
MEMBRANE VERSUS SOLUBLE TNF-ΑLPHA ISOFORMS EXERT 
OPPOSING EFFECTS ON TUMOR GROWTH AND SURVIVAL OF TUMOR 
ASSOCIATED MYELOID CELLS 
 
 
Introduction 
 TNF-α is a major inflammatory cytokine expressed within the tumor 
microenvironment. TNF-α is not normally detected in the serum of healthy 
individuals, but elevated levels have been detected in patients with prostate, 
pancreatic, renal cell, hematopoietic and metastatic breast cancers (Balkwill, 
2006; Bozcuk et al., 2004; Ferrajoli et al., 2002; Michalaki et al., 2004; 
Pfitzenmaier et al., 2003; Yoshida et al., 2002). The role of TNF-α in cancer 
progression is conflicting.  Multiple studies have demonstrated a pro-tumorigenic 
role of TNF-α in vivo, in part by inhibiting necrosis and by stimulating a 
proangiogenic myeloid phenotype (Balkwill et al., 2005; Li et al., 2009). Despite 
the growing body of evidence showing that TNF-α can function as a tumor 
promoter, there remain conflicting findings.  Several case reports describe a 
temporal relationship between development of skin malignancies and lymphoma 
and the use of TNF-α inhibitors (Brown et al., 2002; Chakravarty et al., 2005).  
Moreover, the use of infliximab, which prevents binding of TNF-α to its receptors, 
does not improve clinical outcome in renal cell carcinoma (Larkin et al., 2010). 
Collectively, these data demonstrate the complexity of TNF-α in cancer 
pathogenesis.  
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The majority of studies to date focus on the 17-kDa soluble moiety of TNF-
α, which is released after proteolytic cleavage of the 26-kDa type II 
transmembrane isoform by TNF-α-converting enzyme (TACE; ADAM-17) 
(Kriegler et al., 1988). The role of membrane form of TNF-α and its expression 
pattern in different tissue is poorly understood.  Cardiac-restricted expression of 
membrane versus soluble TNF-α isoform has been shown to have adverse effect 
in cardiac remodeling (Dibbs et al., 2003; Diwan et al., 2004). Expression of 
sTNF-α in cardiomyocytes can cause dilation of left ventricle in mice whereas the 
mTNF-α results in a concentric hypertrophic cardiac phenotype. Increased 
mTNF-α expression on T-cells is shown to modulate monocytes IL10 production 
(Parry et al., 1997). In spite of these findings, the role of mTNF-α in tumor biology 
is unknown (Diwan et al., 2004). Thus far it is not known whether tumors can 
express both isoforms.  In addition there is little understanding of the difference in 
the mechanism of action of sTNF-α versus mTNF-α in regulating tumor behavior 
or impact on the tumor inflammatory stroma.  
The goal of this chapter is to assess if the conflicting data regarding the 
association of TNF-α with tumor progression is due to distinct effects of tumor 
expression of membrane vs. soluble isoforms. In this chapter, we will show that 
different TNF-α isoforms have distinct effect on tumor phenotype. Whereas 
sTNF-α expression promotes tumor growth, mTNF-α-expressing tumors exhibit 
reduced growth and are largely devoid of myeloid cells.  Furthermore, human 
non-small cell lung cancer (NSCLC) tissues exhibit differential expression of 
membrane versus soluble TNF-α and patients with lung tumors predicted by the 
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molecular signature that have higher mTNF-α show a survival rate when 
compared to patients with tumors with higher soluble form of TNF-α expression 
(Ardestani et al., 2013).  
 
Materials and Methods 
Mice and cell lines. Wild-type C57Bl/6 (WT) mice were purchased from Jackson 
Laboratory. Homozygous mutants for TNFR-1 and R-2 knockout (TNFR-DKO) on 
a C57Bl/6 background were a generous gift from Dr. D. Polk. Lewis Lung 
Carcinoma (LLC), B16F10 melanoma, and RAW 264.7 cells were purchased 
from American Type Culture Collection (ATCC) and maintained in DMEM 
supplemented with glucose (4.5 g/l) along with penicillin (10 U/L), streptomycin 
(10 μg/ml), plasmocin (25 μg/ml), amphotericin-B (2.5 μg/ml). H520, HCC95, 
SW900, H157, HCC15, and A549 were provided by Dr. P. P. Massion and were 
maintained in RPMI 1640 medium (Gibco). A549 cells were maintained in Ham's 
F-12K medium (Gibco). All cell lines were supplied with 10% (v/v) fetal bovine 
serum and incubated at 37°C in 5% CO2.  
Constructs and retroviral transductions. Secretable TNF-α was generated by 
replacing amino acids -76 to -1 containing the cytoplasmic signal-anchor for type 
II membrane protein and a short extracellular region with a sequence coding for 
the IL-2 signal peptide (IL2sp, amino acids -20 to -1) that directs the transport of 
TNF-α to the outer cellular space and produces a solely secretable form of 17-
kDa TNF-α.  This was done by amplifying mouse wild-type TNF-α cDNA using 
forward primers flanked by BamH1-IL2sp. The amplified fragment was isolated 
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and purified by gel electrophoresis. The restriction sites at each end allowed 
ligation of the IL2sp-TNF-α fragment into the BamH1-EcoR1 site of LZRS-IRES-
Neo retroviral vector, conferring neomycin resistance. The mTNFΔ1-9, K11E 
sequence encoding a mutant transmembrane TNF-α molecule with a deletion at 
the cleavage site between presequnce and mature membrane TNF-α 
(BCCM/LMBP plasmid collection, Ghent University) was also cloned into LZRS.  
This mutation prevents cleavage of the 26-kDa membrane TNF-α into secretory 
TNF-α isoform. An empty LZRS vector was used as a control vector. 
Surface expression of TNF-α. Cells were detached from tissue culture plate 
and incubated with anti-TNF-α antibody (1 μl/2.5 x 104 cells, Southern Biotech) 
for 30 minutes on ice without permeabilization. PE conjugated secondary 
antibody (0.125 μg/106 cells/100 μl) was added for 30 min on ice. Surface 
expression of TNF-α was measured using flow cytometry. Data are presented as 
percent of viable cells. 
In Vivo murine tumor model.  Control, IL2spTNF-α, and mTNF-α cell lines (106 
cells in 100 µl of PBS) were implanted subcutaneously into WT, TNFR-DKO or 
TNFR-DKO-BMT mice. Mice were sacrificed 15 days post-implantation, tumors 
were excised and the volume was calculated by multiplying tumor length by width 
by height. 
BrdU assay. The BrdU ELISA was performed according to the manufacturer's 
instructions. Briefly, 1000 cells/well were seeded in triplicate in a 96-well plate.  
Cells were allowed to attach for 8 hours. BrdU label was added to each well and 
incubated for an additional 24 hours.  Absorbance was analyzed at 450-540 nm. 
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Cell viability assay. Cell viability was measured by seeding 5000 cells/well in a 
96-well plate for 48 hours. Cells were labeled with 100 μl of PBS containing 0.5 
mg/mL of 3-[4,5-dimethylthiazol-2-yl] 2,5,-diphenyltetrazolium bromide (MTT) 
(Sigma). After 2 hours of incubation at 37°C, cells were lysed with 0.1 ml DMSO. 
Photometric measurement was carried out at 540 nm. 
Leukocyte quantification in tumors. Tumor tissues were finely minced and 
incubated in 5 mL dissociation solution (RPMI medium supplemented with 5% 
FBS, and 1 mg/mL of Collagenase type IV (Worthington)) for 30 min at 37°C. To 
obtain a single-cell suspension, cells were passed through 70-μm nylon cell 
strainer (Becton Dickinson, NJ). Cells were washed with FACS buffer (PBS, 2 
mM EDTA, 0.5% BSA) and incubated for 5 min in RBC lysis buffer solution (155 
mM NH4Cl, 12 mM NaHCO3, 0.1 mM EDTA). Cells were washed twice in FACS 
buffer and incubated with anti-CD3 (Biolegend), -Ly6G (BD Pharminogen), -F480 
(eBioscience) and -CD11b+ (BD Pharminogen). After two washes, labeled cells 
were resuspended in vital dye 7-AAD (BD Pharminogen) and subjected to flow 
cytometry on LSRFortessa flow cytometer (Becton, Dickinson and Company, 
Franklin Lakes, NJ) and analyzed by using FlowJo software (TreeStar, Ashland, 
OR).  
Myeloid cell-trafficking to tumor.  Control vector or mTNF-α-expressing tumor 
cells were injected subcutaneously into wild-type mice. After 12 days, freshly 
isolated myeloid cells were labeled with 5(6)-Carboxyfluorescein N-
hydroxysuccinimidyl ester (CFSE) fluorescent tracking dyes and injected into 
retro-orbital space (5 × 106 cells/animal). Eighteen hours later, tumors were 
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harvested and single-cell suspensions were made. CFSE labeled cells were 
detected using flow cytometry.  
Caspase 3/7 activity. Freshly isolated CD11b+ (105 /96-well) were cocultured 
with fixed control, control+recTNF-α (100 U/mL), and mTNF-α B16F10 cells at 
CD11b+/tumor cells ratio of 1:10 for 5 hours. Apoptosis was quantified in the 
form of caspase-3/7 activation using the Apo-One fluorometric assay system 
from Promega Corporation (Madison, WI) according to the manufacturer's 
protocol. 
Measurement of intracellular ROS. The oxidant-sensing probe CM-H2DCFDA 
(Invitrogen) was used to detect intracellular reactive oxygen species (ROS).   
Freshly isolated CD11b+ cells were loaded with 10 μM CM-H2DCFDA, and 
cocultured with fixed B16F10 control, control+100 U/ml of recombinant TNF-α, 
mTNF-α or mTNF-α+2 mM N-acetyl-cysteine (NAC) for 8 hours. Fluorescence 
was determined using a luminescence spectrophotometer (Spectra max, 
Molecular Devices) with an excitation wavelength of 429 nm and emission 
wavelength of 517 nm.  
Migration assay. Three-μm-pore-size transwells (Costar Corp) were coated with 
fibronectin for 30 min and blocked with 2% (w/v) BSA for 1 hour at room 
temperature. CD11b+ cells isolated from the bone marrow of wild-type mice 
(EasySep, StemCell Technologies) were placed in the upper chambers (105 
cells/well).  Tumor-conditioned media (600 µl/well) from each tumor cell line 
(2x106 cells, 48 hours, 37°C, 5% CO2) were added to the lower chamber.  After 
7 hours of incubation, filters were fixed in 10% formalin and stained in 0.5% 
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crystal violet-0.2M Boric Acid for 30 minutes at room temperature. Migrated cell 
were counted under a high power (40x) lens. 
ROS imaging using confocal microscopy. RAW 264.7 cells were plated 
overnight at a density of 106.  Next day cells were incubated with fixed B16F10 
control, control+100 U/ml of recombinant TNF-α, mTNF-α or mTNF-α+2 mM N-
acetyl-cysteine (NAC). After 8 hours of incubation, cells were washed with PBS 
and loaded with 10 μM solution of CM-H2DCFDA for 20 minutes at 37°C. After 
PBS wash, the remaining attached RAW 264.7 cells were fixed in 1% 
paraformaldehyde and mounted. Cellular fluorescence was monitored at 480/30 
nm (excitation) and 535/40 nm (emission). 
TNF-α cytotoxicity assay. Overnight cultured CD11b+ cells or RAW 264.7 cells 
(2.5x104/100 µL/well, target) were cocultured with Paraformaldehyde-fixed 
(Zhang et al., 2008) control, control+100 U/ml of recombinant TNF-α, mTNF-α or 
mTNF-α+2 mM N-acetyl-cysteine (effector) at target:effector ratio of 1:10 and 
incubated for 48 hours. Cells were labeled with 100 μl of PBS containing 0.5 
mg/mL of MTT for 2 hours at 37°C then lysed with 0.1 ml DMSO and photometric 
measurement was carried out at 540 nm. 
P65/Caspase-3/Bax/Bcl-2 immunoblot analysis. RAW 264.7 cells were plated 
at a density of 106 cells overnight (37°C, 5% CO2).  Fixed control, control + 
recTNF-α (100 U/mL), and mTNF-α B16F10 cells were co-cultured with RAW 
264.7 at T/E ratio of 1:10.  Cells were incubated at 37°C in 5% CO2 for 10 
minutes (p65), 30 minutes (caspase-3), and 6/24 hours (Bax/Bcl-2). After each 
incubation period, RAW 264.7 cells were collected and the whole cell lysate was 
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evaluated for total phospho-NF-κB-p65, total NFκB-p65, caspase-3 (Cell 
Signaling Technology) and Bax/Bcl2 (eBioscience) by Western blot analysis. 
TNF-α ELISA and immunoblotting.  The expression of secretory levels of TNF-
α in human lung caner cell lines was measured in cell cultured supernatant of 
106 cells incubated for 24 hours, using ELISA kit (R&D Systems). 
Transmembrane TNF-α on cell surface of transduced LLC tumor cells was 
analyzed by isolating the membrane fraction protein and subjecting to western 
blot. Cells were lysed in 500 μl of membrane buffer [250 mM Sucrose, 20 mM 
HEPES (7.4), 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1mM DTT, 
PI Cocktail (III)]. Cells were scraped immediately and placed in 1.5 ml eppendorf 
tube. The lysate was passed through a 25 G needle 10 times and incubated on 
ice for 20 minutes. Lysate was spun at 10000 G for 10 min. The supernatant was 
spun in an ultracentrifuge at 100,000 G for 1 hour. The pellet was resuspended in 
50 μl of RIPA buffer [3M NaCl, 1M Tris, 0.5M EDTA, 10% SDS, 1% NP40 
substitute]. 
Immunohistochemistry/fluorescence and morphometry. Paraffin-embedded 
tumor tissues were used for determination of Ki67 (Novocastra), platelet 
endothelial cell adhesion molecule-1 (PECAM-1; clone 557355, Pharmingen), 
CD3 (Santa Cruz), B220b (Pharmingen), ER-HR3 (Santa Cruz), F4/80 
(eBioscience). For immunofluorescence analysis, nuclei were counterstained 
using 4',6-diamidino-2-phenylindole (DAPI; Sigma). The images were visualized 
using a Ziess Axioplan 2 microscope (Carl Ziess MicroImaging). Images were 
photographed with a CoolSNAP Hq CCD camera (Photometrics). For confocal 
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analysis, the LSM510 (Zeiss) microscope was used to capture 1 μm optical slices 
(z stack); the images were analyzed with Metamorph v5.0 (Universal Imaging 
Corp.). Morphometry was performed by obtaining 5 digital images at defined 
magnification taken at random from each section. For morphometric evaluation 
care was taken to exclude regions of necrosis within each field.  
Tissue microarray. The paraffin-embedded tissues were sampled from archived 
conventional tissue blocks. The tissue microarrays were constructed with a 
Beecher instruments tissue arrayer by sampling the three representative areas 
(0.6 mm) of tumor from the original blocks of tumor and transferring them into a 
new array block. TNF-α immunoreactivity was evaluated semiquantitatively 
based on the intensity of staining. It was scored as 1+ (low-moderate), and 2+ 
(intense). Samples with no staining or very weak staining were considered 
negative, and samples with moderate to intense staining were considered 
positive. 
Survival analysis. A cohort published by Shedden et al. was analyzed for 
disease-free survival (Shedden et al., 2008).  The data set included gene-
expression profiles for 442 lung adenocarcinomas with high-quality gene-
expression data, pathological data and clinical information. The association 
between gene expression and the survival was examined using the Cox 
proportional hazard model. Kaplan-Meier curves were generated to visualize the 
survival pattern by dichotomizing the gene-expression. The subgroup analysis of 
mTNF-α and TACE was done by dividing the cohort into 4 groups of high TNF-α 
with high/low TACE or low TNF-α with high/low TACE. Log-rank overall tests 
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were performed for the 4 groups. All statistical analyses were performed using R 
(www.r-project.org). 
Statistical analysis.  The statistical significance between experimental and 
control groups was determined by Student's t-test or ANOVA followed by Tukey’s 
post-test using Prism software (Graphpad, San Diego, CA). A P-value of <0.05 
was considered statistically significant. 
 
Results 
 
Membrane TNF-α isoform reduces tumor growth 
The effects of different TNF-α isoforms on malignant tumor phenotypes 
were investigated using murine Lewis Lung Carcinoma (LLC) sublines 
expressing either sTNF-α (LZRS-IRES-IL2spTNF-α) or mTNF-α (LZRS-IRES-
mTNFΔ1-9) by retroviral transduction (Figure 5A). Cells transduced with empty 
vector (LZRS-IRES-Neo) were used as control. Untransduced LLC cells 
exhibited undetectable levels of TNF-α expression as determined by ELISA.  The 
relative expression of sTNF-α and cell surface expression of TNF-α by 
transduced cells were confirmed by ELISA and flow cytometry respectively. 
sTNF-α expression was detected in IL2spTNF-α-expressing cells at 5 ng/ml. 
Surface expression of TNF-α was not detected in control and IL2spTNF-α tumor 
cells (mean fluorescent intensity of 150 and 202 respectively). In contrast, mTNF-
α-expressing LLC cells displayed 7.1- and 5.3-fold increase in surface TNF-α as 
compared with control and IL2spTNF-α, respectively (Figure 5B).  
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Figure 5. Generation of membrane and soluble TNF-α-expressing cells.  
(A) Schematic representation of TNF-α mutant which has the region coding for 
the TNF-α transmembrane domain (TMD) replaced with region coding for 
interleukin-2 (IL-2) signal peptide to generate soluble TNF-α (sTNF-α) and TNF-α  
lacking TACE cleavage site (Δ1-9, K11E) to generate membrane TNF-α (mTNF-
α). (B) Expression of transmembrane TNF-α on the surface of LLC tumor cells 
transduced with empty vector (control), IL2spTNF-α or mTNF-α vectors was 
analyzed by flow cytometery. 
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To evaluate whether overexpressing various TNF-α isoforms affected 
growth or survival of tumor cells, in vitro proliferation and viability was assessed 
using the BrdU incorporation and MTT assay, respectively. Both IL2spTNF-α- 
and mTNF-α-expressing cells exhibited similar in vitro growth rates compared 
with control LLC lines (P>0.05; Figure 6A). IL2spTNF-α and mTNF-α LLC cell 
lines tested for viability also displayed similar levels of survival rate compared to 
control (P>0.05; Figure 6B). 
To gain additional evidence that the membrane isoform did not reduce 
survival or viability and that these observations were not cell specific,  B16F10-
melanoma cell lines were transduced with retroviral constructs, containing 
mTNF-α or an empty construct as control cells. Similar to LLC lines, the 
proliferation rate (P>0.05) and viability (P>0.05) were not affected in mTNF-α-
expressing B16F10 cells compared to control cells (Figure 7A and B). These 
findings are consistent with earlier studies in which it was shown that 
overexpressing the wild-type TNF-α in both LLC and B16F10 melanoma does not 
alter in vitro growth (Li et al., 2009). 
LLC cell lines expressing soluble (IL2spTNF-α) or membrane (mTNF-α) 
isoforms were implanted subcutaneously into the flank of wild-type C57Bl/6 mice 
(WT). The same number of cells transduced with empty vector was implanted as 
a control.  After 14 days, LLC tumors expressing IL2spTNF-α were ~7 fold 
(1214±122 mm3) larger compared to control tumors (124.4±92 mm3; n=5, 
P<0.0005; Figure 8A).  By contrast, tumors expressing mTNF-α exhibited 65% 
reduction in tumor volume (105.8±29.3 mm3) compared to control tumor  
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Figure 6. Expression of mTNF-α/sTNF-α does not affect proliferation and 
viability in LLC cells. (A and B) Proliferation rate and the viability of transduced 
tumor cells were determined by BrdU and MTT labeling assays respectively. All 
cell lines showed no significant difference in proliferation or viability. Data is 
representative of three independent experiments expressed as the mean±SEM. 
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Figure 7. Expression of mTNF-α does not affect proliferation and viability in 
B16F10 melanoma cells. (A and B) In vitro proliferation (A) and the viability (B) 
of B16F10 cells transduced with control or mTNF-α vectors were determined by 
BrdU and MTT labeling assays, respectively. All cell lines showed no significant 
difference in proliferation (P=0.42) and viability (P=0.16). Data is representative 
of three independent experiments expressed as the mean±SEM. 
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(294.1±35.9 mm3) (n=12, P<0.0005; Figure 8B). Similar growth reduction was 
observed with mTNF-α-expressing B16F10 tumors cell line when compared with 
matched controls (n=7, P<0.05; Figure 8C).  In addition, tumor weight 
measurement followed similar pattern to tumor volume as presented in Figure 
8D-F. These data suggested that different TNF-α isoforms have opposing effects 
on tumor size. 
 
Expression of mTNF-α does not affect tumor proliferation or vascularity  
To evaluated tumor vascular density and tumor cell proliferation rate, 
histological sections from control, IL2spTNF-α and mTNF-α LLC tumor were 
immunostained with platelet/endothelial cell adhesion molecule-1 (PECAM-1) 
antibody to evaluate microvessel density, and anti-Ki67 to assess tumor cell 
proliferation (Figure 9A). Histomorphometry of PECAM-1-positive areas showed 
no difference in vascular density amongst the tumors expressing different TNF-α 
isoforms versus control (P>0.05; Figure 9B). Furthermore, IL2spTNF-α- and 
mTNF-α-expressing LLC tumors showed no significant difference in 
immunoreactivity with the Ki-67 antibody compared to control tumors (P>0.05; 
Figure 9C).  
Vascular density and cell proliferation analyses were also performed 
between B16F10 melanoma-derived tumors expressing mTNF-α versus control 
(Figure 10A). Similar to LLC tumors, no significant difference was observed in 
microvessel density and in vitro proliferation between the control and mTNF-α-
expressing melanoma tumors (P>0.05; Figure 10B and C). 
 35
  
 
 
Figure 8. Membrane TNF-α-expressing tumor cells demonstrate delayed 
tumor growth. (A-C) In vivo growth of tumor cells transduced with control vector 
was compared to LLC lines expressing IL2spTNF-α (A), or mTNF-α (B), and 
B16F10 expressing mTNF-α (C), by subcutaneous implantation in WT C57Bl/6 
mice for 14 days. Tumor weight of (D) LLC control vector/IL2spTNF-α, (E) LLC 
control vector/mTNF-α and (F) B16F10 control/mTNF-α implanted in WT bl/6 
mice. Photomicrograph of each tumor is shown with each experimental group. 
Each point represents an individual animal and the horizontal bar is the median. 
P<0.05, P<0.005,P<0.0005, Student’s t-test.  
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Figure 9. Expression of mTNF-α does not affect tumor proliferation or 
vascularity in vivo. (A) Representative sections of LLC tumors transduced with 
control, IL2spTNF-α and mTNF-α constructs were analyzed by 
immunohistochemistry for PECAM-1 or Ki-67 staining to define vascularity or 
proliferation, respectively. (B and C) Percentage of PECAM-1-positive (B) or Ki- 
67-positive area (C) in control, IL2spTNF-α and mTNF-α in LLC tumors was 
quantitated. There was no significant difference between the cohorts for either 
PECAM-1-positive or Ki-67-positive cells (P>0.05), 1-way ANOVA with Tukey’s 
post-test. 
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Figure 10. Expression of mTNF-α does not affect proliferation and 
vascularity in B16F10 melanoma tumors. (A) Representative sections of 
control, IL2spTNF-α and mTNF-α LLC tumors were analyzed by 
immunohistochemistry for PECAM-1 or Ki-67 staining to define vascularity or 
proliferation, respectively. (B and C) Number of PECAM-1-positive (B) or Ki-67-
positive (C) cells in control, IL2spTNF-α and mTNF-α in LLC tumors were 
quantitated. There was no significant difference between the cohorts for either 
PECAM-1-positive (P=0.37) or Ki-67-positive (P=0.17) cells. 
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Membrane TNF-α-expressing tumors are devoid of tumor associated 
myeloid cells 
 
It is often assumed that TNF-α-mediated tumor promotion is secondary to TNF-α-
mediated inflammation. To determine whether mTNF-α-expressing tumors had 
altered composition of inflammatory cells, we quantified LLC tumor-associated T-
cells (anti-CD3), B-cells (anti-B220b), neutrophils (anti-Ly6G) and myeloid-
monocytic lineage (anti-ER-HR3, CD11b, F4/80) using immunohistochemistry 
staining and flow cytometric analysis of single-cell suspension of tumors. Both 
immunostaining and flow cytometric analysis showed no significant difference in 
T-cell content among control, IL2sp TNF-α and mTNF-α-expressing tumor cells 
(Figure 11A-C). Anti-B220b staining revealed only rare, infiltrating B-cells for all 
tumor groups (data not shown). Flow cytometric analysis of anti-Ly6G showed no 
significant difference in neutrophils population within control and mTNF-α-
expressing tumors (P>0.05; Figure 12). 
Interestingly when tumor-associated myeloid cell population was 
evaluated a significant difference was observed in mTNF-α-expressing tumors 
compared to control and IL2spTNF-α tumors.  Histological staining of mTNF-α-
expressing LLC tumors for ER-HR3, a myeloid marker reactive to ~70% of 
circulating monocytes and a subset of mature tissue macrophages (de Jong et 
al., 1994), had fewer number of infiltrated ERHR3+ cells (0.04±0.02%) versus 
control (6.4±0.37%) or IL2sp-TNF-α tumors (16±1.03%) (P>0.005; Figure 13A 
and B).  
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Figure 11. Tumor derived mTNF-α does not affect T-cell content in tumor. 
(A) Representative sections of control, IL2spTNF-α and mTNF-α-transfected LLC 
tumor cells were analyzed by immunohistochemistry for CD3-positive T-cell 
staining. (B) Number of CD3-positive cells in control, IL2spTNF-α and mTNF-α in 
LLC tumors was quantitated. There was no significant difference between the 
cohorts for CD3-positive cells. (C) Representative flow cytometric analysis of 
CD3-positive T-cells in LLC tumor cell suspension. Dot plots show CD3/7-AAD 
population in control (left) and mTNF-α (right) tumors. 
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 Figure 12. Tumor derived mTNF-α does not affect neutrophil content in 
tumor. Quantification of flow cytometeric analysis of Ly6G-positive neutrophils in 
LLC tumor cell suspension. 
 
 
Figure 13. Membrane TNF-α-expressing tumors are devoid of ER-HR3-
positive myeloid cells. (A) ER-HR3 staining of LLC tumor cells, expressing 
various TNF-α isoforms. Control (left), IL2spTNF-α (middle), and mTNF-α (right) 
LLC tumor sections from wild-type bl/6 were stained with ER-HR3 myeloid 
markers (green). (B) Percentage of ER-HR3-positive cells in LLC tumors 
transduced with control or different of TNF-α isoforms was quantitated. There 
was a significant decrease in the number of ER-HR3-positive cells in LLC tumors 
expressing mTNF-α isoform compared to control tumors. 
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Further evaluation of single-cell suspension of tumors showed significantly lower 
number of CD11b+ myeloid cells (52.17±6.1%; P>0.005) and F4/80 
macrophages (3.75±2.4%; P>0.005) in mTNF-α-expressing tumors as compared 
to control (Figure 14A-D). Anti-F4/80 staining of tumor sections further confirmed 
the significant reduction of F4/80-positive macrophages in mTNF-α expressing 
tumors (Figure 14E and F). 
To test whether the tumor inhibitory effects of mTNF-α required the 
presence of TNF-α receptors, tumor growth was assessed in TNF-α receptors 
deficient mice (TNFR-1 and TNFR-2 double knockout, TNFR-DKO).  Mice were 
implanted with LLC cell line expressing various TNF-α isoforms. LLC lines 
expressing mTNF-α isoform did not generate significantly smaller tumors 
(110.5±17.6 mm3) when compared with their paired control tumors (161.7±29.6 
mm3, n=5) (P>0.05; Figure 15A). In addition, implantation of mTNF-α-expressing 
LLC tumor cells in TNFR-DKO mice restored the ER-HR3+ myeloid population in 
mTNF-α-expressing tumors (0.91±0.16% ER-HR positive area/total area in 
mTNF-α vs. 0.67%±0.16% in control; P>0.05; Figure 15B). Similar results were 
observed in B16F10 line (data not shown).  
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Figure 14. Membrane TNF-α-expressing tumors are devoid of CD11b- and 
F4/80-positive myeloid cells. (A and C) Representative flow cytometric 
analysis of CD11b- and F4/80-postitive population in LLC tumor cell suspension. 
Dot plots show CD11b/7-AAD (A) and F4/80/7-AAD (C) from one representative 
animal for each group. (B and D) Percentage of CD11b- and F4/80-positive cells 
were quantitated in control and mTNF-α tumor cell suspensions. (E) 
Representative sections of control and mTNF-α-transfected LLC tumors were 
analyzed by immunohistochemistry for F4/80+ macrophages. (F) Number of 
F4/80-postivie cells in control and mTNF-α in LLC tumors was quantitated. Data 
are presented as mean±SEM, **P<0.005, ***P<0.0005; Student’s t-test. 
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Figure 15. Tumor inhibitory effect of mTNF-α requires the presence of TNF-
α receptors. (A) Control and mTNF-α-expressing LLC tumor cells were 
implanted subcutaneously in TNFR-DKO mice for 14 days. The average±SEM 
are shown for each group (n=5 animals). (B) Morphometric quantification of ER-
HR3 staining of control or mTNF-α-expressing LLC tumor, from TNFR-DKO mice. 
Student’s t-test. 
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Restoration of myeloid cell population in mTNF-α-expressing LLC tumors 
in TNFR-DKO host prompted us to further evaluate the requirement of TNFR 
signaling in inflammatory cells (i.e bone marrow-derived cells). Therefore, tumor 
growth was assessed in WT mice receiving bone marrow (BM) transplants from 
TNFR-DKO mice (referred to as BMT-TNFR-DKO mice). Similar to experiments 
in TNFR-DKO host, LLC line expressing mTNF-α isoform, implanted into BMT-
TNFR-DKO, did not generate smaller tumors in mice engrafted with TNFR-
deficient BM (497.2±137.6 mm3) as compared with control tumors (387.9±95.94 
mm3) (P>0.05; Figure 16A). Furthermore, tumor associated myeloid cell 
populations were quantified in BMT-TNFR-DKO mice. The overall percentage of 
myeloid populations in mTNF-α-expressing LLC tumors (7.8±0.4%) was similar to 
control tumors (7.5±1.4%) (P>0.05; Figure 16B and C). These data suggested 
that tumor derived mTNF-α significantly reduced myeloid population within the 
tumor microenvironment. Since this effect was abrogated in WT mice 
transplanted with TNF-α receptor deficient BM, it could be concluded that intact 
TNF-α signaling through its receptor in bone marrow derived cells was required 
for this effect, and that this effect was not mediated by secondary factors from 
the tumor cells.  
 
Membrane TNF-α-derived soluble factors do not affect CD11b+ myeloid cell 
migration/recruitment  
 
One possible explanation for the reduction of myeloid cells observed in 
mTNF-α-expressing tumors was that such tumors exhibited reduced expression 
of necessary signals for myeloid recruitment. Using a modified Boyden chamber 
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Figure 16. Tumor-inhibitory effects of mTNF-α requires signaling between 
TNF-α and its cognate receptors.  (A) Control and mTNF-α-expressing LLC 
tumor cells were implanted subcutaneously in WT bl/6 mice received bone 
marrow (BM) transplant from TNF-α receptors1/2 knockout donor (BMT-TNFR-
DKO mice) for 14 days. The mean is shown for each group (n=6 animals). (B) 
Representative ER-HR3 immunofluorescence staining from control and mTNF-α-
transduced tumors. (C) Percentage of ER-HR3-positive cells in control and 
mTNF-α-expressing LLC tumors from WT mice with BMT from TNFR-DRKO 
donor was quantitated. There was no significant difference between the cohorts 
for ER-HR3-positive cells (n=3). Data are presented as mean±SEM, Student’s t-
test. 
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assay, the ability of conditioned media (CM) from LLC and B16F10 melanoma 
cell lines expressing various forms of TNF-α to promote migration (i.e. 
recruitment) of primary murine CD11b+ myeloid cells was evaluated. CM from 
mTNF-α did not inhibit migration of CD11b+ as compared to control-CM in both 
LLC and B16F10 melanoma line (Figure 17A and C). An increase in CD11b+ 
myeloid cells migration was observed in CM derived from both IL2spTNF-α-
expressing LLC (~1.5-fold; Figure 17B) and B16F10 line (~4-fold; Figure 17D). 
This may be attributed to the presence of TNF-α itself, which is known to induce 
chemotactic response (de Jong et al., 1996; Torrente et al., 2003). These results 
suggested that the relative paucity of myeloid cells in mTNF-α-expressing tumors 
was likely not due to reduced expression of key cytokines, necessary for myeloid 
extravasation and migration into the tumor.  
Next, the ability of control and mTNF-α-expressing LLC tumors to 
effectively recruit myeloid cell in vivo by adoptive transfer of CFSE labeled 
CD11b+ into tumor bearing mice was evaluated. After 18 hours post injection 
CFSE-positive myeloid cells were quantified in each tumor type by flow analysis 
of single-cell suspension of tumor digests.  The overall number of CFSE-positive 
cells in mTNF-α-expressing LLC tumors (58±21) was similar to control tumors 
(68±12.57) (P>0.05; Figure 18A and B). These data demonstrate that reduced 
myeloid cells in mTNF-α-expressing tumors was not due to impaired recruitment 
of circulating cells.  
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Figure 17. Soluble factors derived from mTNF-α do not affect the rate of 
CD11b+ myeloid cell migration compared to control. (A and B) Transwell 
migration assay of primary CD11b+ cells treated with conditioned media derived 
from LLC tumor cells transduced with control/mTNF-α (A) or cotnrol/IL2spTNF-α 
(B) constructs. (C and D) Transwell migration assay of primary CD11b+ cells 
treated with conditioned media derived from B16F10 tumor cells transduced with 
control/mTNF-α (C) or cotnrol/IL2spTNF-α (D) constructs. Data presents the 
mean±SEM. 
 
 
 
 
 48
  
 
 
Figure 18. Reduced myeloid cells in mTNF-α-expressing tumors is not due 
to impaired recruitment of circulating cells. (A) Representative flow 
cytometric analysis of CFSE-positive cells presented in LLC tumor suspension 
expressing either control (left) or mTNF-α (right) isoform. (B) Quantification of 
CFSE-positive cells detected in a given number of tumor suspension (n=3 for 
each tumor type). Data are presented as mean±SEM, P>0.05. 
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Membrane TNF-α induces cell death through apoptosis-independent 
pathway 
 
To investigated if the distinct TNF-α isoforms exerted cytotoxic effects on 
myeloid cells, freshly isolated CD11b+ cells (target) were mixed with 1% 
paraformaldehyde-fixed B16F10 melanoma cells (effector) expressing empty 
vector with or without 100 U/ml recombinant murine TNF-α,  (FxB16cont or 
FxB16cont+rTNF-α) or fixed mTNF-α-expressing B16F10 cells (FxB16mTNF) at an 
effector:target ratio of 10:1. As measured by the MTT assay (Figure 19A), 
FxB16mTNF resulted in more than 60±29% cytotoxicity of CD11b+ myeloid cells 
after 48 hours of incubation, as compared to CD11b+ cells incubated with 
FxB16cont (P<0.005). CD11b+ in the presence of FxB16cont+rTNF-α showed less 
than 1% cytotoxicity in compared to control. The activation of apoptotic pathway 
as the mechanism of mTNF-α-induced myeloid cell death by determining the 
caspase-3/7 enzymatic activity in CD11b+ cells was assessed. Compared to 
control, CD11b+ myeloid cells cocultured with FxB16cont+rTNF-α or FxB16mTNF 
did not show any significant increase in the level of caspase 3/7 activity (P>0.05, 
Figure 19B).  
To assess the activation of apoptotic pathway in RAW 264.7 cells, the 
level of Bax/Bcl-2of and cleavage/activation of caspase-3 proteins in RAW 264.7 
was determined. The data suggested that the Bax/Bcl-2 ratio (Figure 20A) and 
active-caspase-3 (Figure 20B) proteins in RAW 264.7 cells treated with both 
soluble and membrane TNF-α had no significant changes when compared to 
control. Together these findings are indicative of another death pathway 
independent of apoptosis.  
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Figure 19. Membrane TNF-α induces cell death through apoptosis-
independent pathway. (A) Cytotoxic effect of sTNF-α and mTNF-α on CD11b+ 
cells measured by MTT assay. (B) Caspase-3/7 activity (relative fluorescence 
unit [RFU]) in CD11b+ cocultured with Paraformaldehyde-fixed control 
(FxB16cont), control+rTNF-α (FxB16cont+TNF-α), or mTNF-α (FxB16mTNF). Data 
is representative of three independent experiments expressed as the mean±SEM. 
P<0.05, 1-way ANOVA with Tukey’s post-test. 
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NF-κB is a critical factor in the determination of cell death versus survival 
and proliferation (Karin and Lin, 2002; Senftleben and Karin, 2002). In cases of 
failed NF-κB activation, TNF-α can induce either programmed cell death or 
necrosis through complex signal transduction cascades (Gupta, 2002). To 
evaluate whether soluble versus mTNF-α isoforms induced distinct cellular 
responses via regulation of NF-κB, we tested NF-κB activity in RAW 264.7 cells 
co-cultured with FxB16cont, FxB16cont+rTNF-α, or FxB16mTNF. As shown in Figure 
20C, the level of NF-κB p65 phosphorylation activity in RAW 264.7 cells 
stimulated with both FxB16cont+rTNF-α and FxB16mTNF was similar to FxB16cont, 
suggesting that mTNF-α isoform did not affect the activity of NF-κB p65 
compared to sTNF-α.  
 
Membrane TNF-α-induced cell death occurs through induction of ROS 
TNF-α can induce cell death by induction of intracellular reactive oxygen 
spices (ROS)(Corda et al., 2001; Deshpande et al., 2000).  To test the possibility 
that soluble versus membrane TNF-α isoforms induced distinct cellular 
responses via regulation of intracellular ROS, we evaluated ROS levels in 
CD11b+ myeloid cells incubated with different TNF-α isoform by measuring CM-
H2DCFDA fluoresce.  In CD11b+ cell incubated with FxB16cont+rTNF-α, the CM-
H2DCFDA fluorescence did not differ from control, whereas in cells with 
FxB16mTNF a 1.6-fold increase was observed after 8 hours of incubation (P<0.05; 
Figure 21A). Addition of N-acetyl-cysteine into cells cultured with FxB16mTNF  
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Figure 20. Kinetics of NFκB, caspase-3 and BAX/Bcl-2 activation in mTNF-α 
stimulated RAW 264.7. FxB16cont, FxB16cont+rTNF-α, or FxB16mTNF was 
added for indicated incubation period. RAW 264.7 cells were harvested and total 
cellular protein was analyzed for Bax/Bcl-2 ratio (A), activated caspase-3 (B), 
and total and phopho- NF-κB p65 (C). Immunoblot analysis showed no 
differences in Bax/Bcl-2 ratio or caspase-3 and NF-κB pathway activation with 
different TNF-α isoforms compared to control. 
 
 
 
 
 
 53
significantly decreased the intensity of CM-H2DCFDA fluorescence indicating 
decrease in the level of ROS (P>0.05). NAC treatment of FxB16mTNF treated  
CD11b+ reduced mTNF-α induced cytotoxicity (FxB16mTNF, 61.57±29.12% 
cytotoxicity; FxB16mTNF+NAC, 10.64±29.17% cytotoxicity; P<0.05; Figure 21B).   
In addition, ROS generation in individual RAW 264.7 by CM-H2DCFDA 
fluorescent staining assay was evaluated (Kim et al., 2005). The fluorescent 
intensity in RAW 264.7 co-cultured with FxB16cont+rTNF-α was similar to the 
basal level (4.6±3%). However in the presence of FxB16mTNF, we observed an 
induction of ROS intensity (82.5±15%) as detected by the presence of green 
fluorescence staining (Figure 22A and B). Treatment of RAW 264.7 cocultured 
with FxB16mTNF cells supplied with the ROS scavenger N-acetyl-cysteine 
(FxB16mTNF+NAC) diminished mTNF-α-induced accumulation of intracellular 
ROS in RAW 264.7(0.5±0.4%; Figure 22A and B) and led to abolition of mTNF-α 
induced cytotoxicity (FxB16mTNF, 34±9% cytotoxicity; FxB16mTNF+NAC, 0.1±7% 
proliferation; P<0.05; Figure 22C).   
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Figure 21. Membrane TNF-α-induced cell death occurs through induction of 
ROS. (A) Effects of various TNF-α isoforms on intracellular ROS generation in 
CD11b+ cells. Cells were labeled with ROS detection reagent, CM-H2DCFDA, 
and incubated with FxB16cont, FxB16cont+TNF-α, or FxB16mTNF, FxB16mTNF+N-
acetyl-cysteine (NAC, 2mM) and then ROS level was quantitatively analyzed. (B) 
Cytotoxic effect of mTNF-α on CD11b+ cells decreased in the presence of ROS 
scavenger NAC. Data is representative of three independent experiments 
expressed as the mean±SEM. P<0.05 and P<0.005, 1-way ANOVA with 
Tukey’s post-test. 
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Figure 22.  ROS level in mTNF-α treated RAW 264.7. 
(A) Fluorescent micrographs of RAW 264.7 (blue: DAPI nuclear staining) 
incubated for 8 hours with FxB16cont, FxB16cont+rTNF-α, or FxB16mTNF, 
FxB16mTNF+NAC (2mM) and subsequently treated with ROS detection reagent, 
CM-H2DCFDA (green). (B) Intensity of CM-H2DCFDA was quantitated. Increase 
in number of ROS generating cell was detected in RAW 264.7 cocultured with 
mTNF-α-expressing B16F10 cells which was reversed by addition of NAC. (C) 
Cytotoxic effect of mTNF-α on RAW 264.7. P<0.05, and P<0.0005, 1-way 
ANOVA with Tukey’s post-test. 
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Relative expression pattern of TNF-α/TACE correlates with survival 
probability in lung cancer patients 
 
In most studies, the role of TNF-α in cancer has only been investigated in 
murine models or in modified cell lines and to our knowledge the expression level 
of mTNF-α has not been evaluated in human tumors. To extend the relevance of 
these findings from the murine model to human cancer, 62 tissue cores available 
in a single human non-small cell lung carcinoma (NSCLC) tissue array containing 
squamous cell carcinoma, large cell carcinoma, and adenocarcinoma were 
examined.  
Using co-immunofluorescent staining analysis with anti-TNF-α and 
carcinoma-enriched membrane antigen (EMA) the distribution of both degree 
(high- or low-expressors) and localization (membrane, cytoplamic or both) of 
TNF-α staining were evaluated (Figure 23A). Forty of 62 individual tumors were 
positive for TNF-α expression. Among 40 tumors, expressing either high or low 
TNF-α, tumors presenting high levels of membrane-localized TNF-α, tumors 
presenting high cytoplasmic TNF-α (i.e. tumors with higher expression of sTNF-
α) or tumors with cytoplasmic and membrane-localized TNF-α were detected. 
Eighteen of the 40 tumors (45%) were high expresser with 27.8% cytoplasmic 
localization, 16.7% localized on the membrane and 55.5% were positive for both 
membrane and cytoplasmic TNF-α. Twenty two (65%) showed low expression of 
TNF-α with 18.3% cytoplasmic, 31.8% membrane and 50% with both membrane 
and cytoplasmic (Figure 23B).  These data are the first evidence for the 
existence of mTNF-α in human tumors and that its level varies significantly from 
patient to patient. Moreover, its level and localization varies significantly from 
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patient to patient, which is likely an important consideration in predicted 
therapeutic response to anti-TNF-α agents based on our pre-clinical 
observations.  
To provide further evidence that human tumors exhibit varying expression of 
TNF-α isoforms, the expression of sTNF-α was determined by ELISA of CM and 
the expression of mTNF-α was evaluated by immunoblot analysis of cell 
membrane fraction.  The analysis showed significant variation in the relative 
expression of membrane versus soluble TNF-α among different human lung 
cancer-derived cell lines (Figure 23C).  
The possible association of sTNF-α versus mTNF-α ratio with patient 
outcome was investigated (Shedden et al., 2008). It has been shown that there is 
a positive correlation between TACE surface expression and TNF-α cleavage. 
Upregulation of TACE protein has also been shown to be associated with a 
decline in mTNF-α level and increased soluble level and vice versa (Armstrong et 
al., 2006).  Using publicly accessible NSCLC microarray database (n=442 
patients), the gene expression data were divided into four groups. The first two 
groups featured low TNF-α gene expression and low or high TACE. The third and 
fourth groups demonstrated high TNF-α with either low or high TACE. Over all 
higher TACE level was significantly correlated to lower survival probability. 
Expression of high TNF-α/low TACE — representing tumors with high mTNF-
α:sTNF-α relative expression — was associated with longer survival than 
expression of high TNF-α/high TACE — representing tumors with low mTNF-
α:sTNF-α relative expression (log rank P=0.035; Figure 24). 
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Figure 23. Human NSCLC express various levels of membrane and soluble 
TNF-α. Analysis of TNF-α expression from 40 human non-small cell lung 
carcinoma (NSCLC) tissue array. Using co-immunofluorescent staining analysis 
the distribution of both degree (high- or low-expressors) and localization 
(membrane, cytoplamic or both) of TNF-α staining were evaluated. (A) Selected 
example of a membrane TNF-α expression (top) and a cytoplasmic TNF-α 
expression (bottom) in tumors using co-immunofluorescent staining analysis with 
anti-TNF-α (red) and carcinoma-enriched membrane antigen (EMA-green). (B) 
Graph displays the distribution of both degree and localization of TNF-α staining 
40 NSCLC patient samples. (C) Expression pattern of sTNF-α and mTNF-α in 
human NSCLC cell lines measured by ELISA and immunoblotting methods, 
respectively. Variation was observed in the ratio of mTNF-α to sTNF-α expressed 
by each cell line. 
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Figure 24. Relative expression pattern of TNF-α/TACE correlates with 
survival probability in lung cancer patients.  
Association between TNF-α and TACE co-expression pattern and survival 
probability in patients with NSCLC. Analysis of the publicly available data from 
the Shedden cohort was used to correlate TNF-α/TACE expression pattern with 
survival probability (n=442, log rank P=0.035). 
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Discussion 
Data from both experimental and human cancers have identified TNF-α as 
key cytokine modulating tumor progression, yet its effects are incompletely 
understood.  In murine models, deletion or inhibition of TNF-α reduces the 
incidence of cancer formation and even increases resistance to chemically 
induced carcinogenesis of the skin (Arnott et al., 2004; Moore et al., 1999). 
Consistent with this, there was a positive correlation between level of TNF-α 
expression and tumor grade in ovarian tumors (Naylor et al., 1993).  On the other 
hand, anti-tumorigenic properties of TNF-α are also well-documented. In a study 
by Boldrini et. al, assessment of TNF-α expression in 61 NSCLC samples 
demonstrated expression of TNF-α in 45.9% of cases and directly correlated with 
a better clinical outcome (Boldrini et al., 2000).  
Many soluble proteins such as TNF-α are originally expressed as a 
membrane-bound form and then processed to a secretory form through 
proteolytic cleavage. Some of these proteins such as Fas ligand, a member of 
TNF-α super family, have been described to have distinct biological effects on 
disease process as a membrane isoform when compared to the soluble isoform 
(LA et al., 2009). In this chapter we sought to better understand the role of 
different TNF-α isoforms in the modulation of tumor progression and to determine 
if some of the reported opposing effects can be attributed to distinct effects of 
these isoforms. 
Here, it was shown that subcutaneous implantation of mTNF-α expressing 
LLC and B16F10 cancer cell lines expressing uncleavable mTNF-α generates 
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significantly smaller tumors and this was not the result of impaired angiogenesis 
or reduced tumor cell proliferation but was driven by components of the host 
derived cells.  This idea was further strengthened by significant reduction of 
tumor associated myeloid cell content in mTNF-α-expressing tumors which were 
restored in tumor cells transplanted in TNFR-DKO mice. Numerous studies have 
shown critical roles for tumor-associated stromal cells, specifically, bone marrow-
derived myeloid cells, in tumor growth (De Palma et al., 2005; Shojaei et al., 
2008).  Upon activation by cancer cells, tumor-associated macrophages can 
release growth factors, cytokines and inflammatory mediators that may facilitate 
cancer cell invasion, migration, angiogenesis, tumor progression or metastasis 
(Condeelis and Pollard, 2006; Wang et al., 2005; White et al., 2001). 
Furthermore, systemic depletion (Zeisberger et al., 2006) or inhibition (Allavena 
et al., 2005) of tumor associated myeloid cells migration into the tumor has 
shown to significantly reduce tumor growth. In light of our findings, it would be of 
great interest to determine the precise role of myeloid cells in mTNF-α-mediated 
tumor growth. 
The presented data in this chapter revealed that tumor cell expression of 
the membrane isoform of TNF-α resulted in tumor associated myeloid cell death 
through increased ROS production.  It has been shown that TNF-α has the ability 
to induce necrotic cell death by utilizing death domain-containing adaptor 
proteins such as RIP1, TRADD and FADD upon TNFR activation. Once recruited 
to the TNFR death domain further downstream events lead to ROS generation 
and cell death (Festjens et al., 2006; Lin et al., 2004; Morgan et al., 2008). 
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Multiple pathways have been shown to lead to ROS generation upon TNFR 
activation (Corda et al., 2001; Vanden Berghe et al., 2007). Necrotic cell death 
induced by TNFR has been associated with generation of ROS derived from 
either mitochondrial or non-mitochondrial sources (Schwandner et al., 1998; 
Vanden Berghe et al., 2007). Mitochondrial complex I-mediated generation of 
ROS has been linked to direct activation by TNFR and ceramide mediated 
activation (Festjens et al., 2006; Morgan et al., 2008). In a study by Kim et al., 
TNFR was reported as an activator of Nox1 NADPH oxidase complex in a 
TRADD-and RIP1-dependent recruitment (Kim et al., 2009).  The presented 
findings suggest that the membrane form of TNF-α is very efficient at stimulating 
ROS generation and initiating necrotic cell death. This could be due to the ability 
of mTNF-α to recruit death domain-containing adaptor proteins more efficiently or 
mTNF-α activates a pathway that is more efficient in ROS generation. The 
mechanistic pathway(s) which leads to mTNF-α induced ROS generation 
requires further investigation.  
There has not been any study evaluating the relative expression of soluble 
and membrane TNF-α during tumor progression in human cancer, including 
analyses designed to determine if there is any correlation between the level of 
sTNF-α versus mTNF-α and the cancer outcome. Here, the in vivo tissue array 
staining and in vitro assessment of soluble and membrane TNF-α expression in 
human NSCLC cell lines showed that the ratio of soluble to membrane TNF-α 
varies among different tumor cell types. Furthermore, we verified this by 
immunofluorescence staining of tumor section for TNF-α. The fact that mTNF-α 
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is present in tumor and at different levels and subcellular localization may 
provides important clues to divergent outcomes seen in TNF-α positive tumor 
phenotype seen in different patients.  
  In order to generate sTNF-α, the membrane associated TNF-α is cleaved 
through proteolytic activity of TACE.  Although it has been suggested that other 
proteinases are capable of TNF-α cleavage it has been shown that TACE has the 
highest affinity for TNF-α ectodomain shedding among the other known substrate 
(Armstrong et al., 2006). Level of TACE present on the surface of the membrane 
has been inversely correlated with the level of membrane associated TNF-α and 
inhibition of TACE by MMP inhibitors has demonstrated a transient increase in 
mTNF-α surface expression (Armstrong et al., 2006; Solomon et al., 1997). 
These studies suggest that the regulation of TACE activity and subsequent 
alteration of the sTNF-α to mTNF-α ratio could have a great impact on tumor 
growth. The association between higher TACE and higher TNF-α gene 
expression in NSCLC and decreased survival further confirms the importance of 
different TNF-α isoforms availability on tumor regulation.   
As discussed in previous chapter antitumor therapy in clinical trial has 
been unsuccessful, suggesting that in order to take this forward, we need to 
identify those patients who are most likely to benefit from TNF-α antagonist 
treatment.  Perhaps determining the predominant form of TNF-α expressed by 
tumor in these patients would be beneficial for a more effective treatment with 
TNF-α inhibitors which can block both soluble and membrane isoforms.   
 64
 In summary, it was shown that TNF-α membrane versus soluble isoforms 
have opposing effects on cancer growth.  Expression of both forms of TNF-α in 
NSCLCs indicates that this finding is relevant to human malignancies and that 
isoform analysis should be applied to identify candidates for which anti-TNF-α 
agents are likely to be beneficial versus detrimental. 
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CHAPTER III 
 
MEMBRANE TNF-ALPHA-ACTIVATED PROGRAMMED NECROSIS IS 
MEDIATED BY CERAMIDE-INDUCED REACTIVE OXYGEN SPECIES 
 
Introduction 
Tumor necrosis factor-alpha (TNF-α) is an inflammatory cytokine, that 
activates cell inflammation, proliferation, survival and cell death depending on 
autocrine/paracrine signals, and on the cellular context (Rangamani and Sirovich, 
2007; Wallach et al., 1999). The soluble homotrimeric form of TNF-α (sTNF-α) 
that is released from the cell surface activates multiple signal transduction 
pathways including NF-B survival pathway. In addition to activation of cell 
survival pathways, sTNF-α can induce cell death (Balkwill, 2009; Baud and Karin, 
2001). Activation of caspases and initiation of apoptosis has been described as 
the classic form of TNF-mediated cell death. Recent evidence suggests that 
sTNF-α can also trigger an alternative form of cell death that is distinct from 
apoptosis. This form of cell death is referred to as “programmed necrosis” and is 
dependent on the generation of reactive oxygen species (Morgan et al., 2008; 
Wu et al., 2012).  
So far, in the majority of studies TNF-α-mediated programmed necrosis 
have been attributed to the biological and mechanistic function of sTNF-α and its 
interaction with TNFR-1 in the presence of pharmacological or genetic inhibition 
of apoptosis (Arnott et al., 2004; Chan et al., 2003). TNF-α can also exist as a 
membrane-anchored protein. (Horiuchi et al., 2010; Perez et al., 1990). Like 
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sTNF-α, membrane TNF-α is biologically active and binds either of the two TNF-
receptors. The study presented in the previous chapter indicated that human lung 
NSCLC express both soluble and membrane isoforms. Using a murine lung 
cancer model it was shown that unlike sTNF-α, mTNF-α exhibits inhibitory effects 
on tumor growth and myeloid content. We demonstrated that mTNF-α efficiently 
induced myeloid cell death through induction of ROS-mediated necrosis in the 
absence of any apoptosis inhibitors. Currently nothing has been reported on how 
mTNF-α mediates programmed necrosis.  
Soluble TNF-α-induced programmed necrosis typically occurs where 
apoptosis is inhibited, and is mediated through a few defined pathways. In all 
cases, the serine/threonine kinase receptor interacting protein-1 (RIP-1) has 
been shown to play a central role in initiation of programmed necrosis (Li et al., 
2012; Moquin and Chan, 2010), mainly through nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase (NOX) or mitochondria (Fan et al., 
2002; Frey et al., 2002; Hordijk, 2006; Kim et al., 2007). Recent studies have 
also described a role for ceramide-mediated programmed necrosis. An increase 
in the level of intracellular ceramide has been linked to increased redox reaction 
within the cell (Garcia-Ruiz et al., 1997; Huwiler et al., 1999), suggesting the 
potential for crosstalk between ceramide, ROS, and TNF-α pathways in this 
process. In spite of these observations, the specific mechanism by which 
ceramide signaling leads to increased redox reactions is not fully understood. 
In this chapter we will determine the molecular pathway involved in mTNF-
α-mediated oxidative stress-induced cell death. Using inhibitors targeting 
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mitochondrial electron transport chain and NADPH oxidase we present evidence 
that mitochondrial-dependent oxidative stress is the major source of mTNF-
induced intracellular ROS generation, regulated by ceramide-activated protein 
kinase (CAPK) activity (Ardestani, under review).   
 
Materials and Methods 
Mice, cell lines and materials. Wild-type C57Bl/6 (WT) mice were purchased 
from Jackson Laboratory. Homozygous mutants for TNFR-1, TNFR-2, and 
TNFR-1/2 double knockout (TNFR-DKO) on a C57Bl/6 background were a 
generous gift from Dr. D. Polk. B16F10 melanoma, RAW264.7 and L929 cells 
were purchased from American Type Culture Collection (ATCC) and were 
maintained in DMEM with 10% (v/v) fetal bovine serum, heat inactive fetal bovine 
serum and MEM with 10% (v/v) horse serum, respectively. N-Acetyl-L-cysteine 
(NAC), 2-Thenoyltrifluoroacetone (TTFA), myxothiazol and 4-
(Dimethylamino)pyridine (DMAP) were purchased from Sigma-Aldrich and 
prepared fresh on the day of the experiment.  
Constructs. Membrane TNF-α-expressing cells were generated by cloning the 
mTNFΔ1-9, K11E sequence encoding a mutant transmembrane TNF-α protein 
with a deletion at the cleavage site between pre-sequence and mature 
membrane TNF-α (BCCM/LMBP plasmid collection, Ghent University) into the 
BamH1-EcoR1 site of LZRS-IRES-Neo retroviral vector, conferring neomycin 
resistance. This mutation prevents cleavage of the 26-kDa membrane TNF-α into 
secretory TNF-α isoform. An empty LZRS vector was used as a control vector. 
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Surface expression of TNF-α. Trypsinized cells were incubated with anti-TNF-α 
antibody (1 μl/2.5 x 104 cells, Southern Biotech) for 30 minutes on ice. PE 
conjugated secondary antibody (0.125 μg/106 cells/100 μl) was added for 30 
minutes on ice. Surface expression of TNF-α was measured using flow 
cytometry. 
TNF-α cytotoxicity assay. Overnight cultured RAW 264.7, L929 or freshly 
isolated bone marrow CD11b cells (EasySep, StemCell Technologies) 
(2.5x104/100 µL/well, target) were cocultured with Paraformaldehyde-fixed 
(Zhang et al., 2008) control, control+100 U/ml of recombinant TNF-α or mTNF-α 
(effector) at target:effector ratio of 1:10 and incubated for 48 hours. Cells were 
labeled with 100 μl of PBS containing 0.5 mg/mL of 3-[4,5-dimethylthiazol-2-yl] 
2,5,-diphenyltetrazolium bromide (MTT) (Sigma) for 2 hours at 37°C then lysed 
with 0.1 ml DMSO.  Photometric measurement was carried out at 540 nm. 
Percentage of cell death was calculated by using the following formula: Cell 
death (%) = (1 – ODsample/ODcontrol) x 100.   
Lactate dehydrogenase (LDH) assay. Early cell damage was determined using 
the LDH cytotoxicity detection kit (Promega, Madison, WI), which quantifies the 
LDH release from the cells into the culture medium. Cells were seeded in a 96-
well plates at a density of 2.5x104 cells/well overnight to promote adherence. 
Cells were cocultured with fixed B16F10 control or mTNF-α in the absence or 
presence of the indicated treatments for 24 hours. Supernatants from the 
cultures were collected and used in the LDH assay as instructed by the 
manufacturer. LDH activity was detected separately in the supernatant and cell 
 69
lysate. The percentage of LDH leakage was calculated as 100 x (LDH supernatant / 
(LDH supernatant + lysate)).  
Measurement of intracellular ROS. The oxidant-sensing probe CM-H2DCFDA 
(Invitrogen) was used to detect intracellular reactive oxygen species (ROS). An 
overnight culture of cells (2.5x104) were loaded with 10 μM CM-H2DCFDA for 30 
minutes and cocultured with 2.5x105 fixed B16F10 control or mTNF-α-expressing 
cell in the absence or presence of the indicated treatments for 6 hours. 
Fluorescence was determined using a luminescence spectrophotometer (Spectra 
max, Molecular Devices) with an excitation wavelength of 495 nm and emission 
wavelength of 525 nm.  
Immunoblot analysis. Target cells were plated at a density of 106 cells 
overnight (37°C, 5% CO2).  Cells then were treated with fixed control or mTNF-α-
expressing B16F10 at target cell/fixed tumor cell ratio of 1:10.  After 30 minutes 
incubation at 37°C, target cells were lysed with RIPA buffer [3 M NaCl, 1 M Tris, 
0.5 M EDTA, 10% SDS, 1% NP40 substitute and 1× Complete Protease Inhibitor 
Cocktail (Roche)]. Whole cell lysate was evaluated for caspase-3 cleavage (Cell 
Signaling Technology) and RIP-1 (BD biosciences) by Western blot analysis.  
Statistical analysis. The statistical significance between experimental and 
control groups was determined by Student's t-test or ANOVA followed by Tukey’s 
post-test using Prism software (Graphpad, San Diego, CA). A P-value of <0.05 
was considered statistically significant. 
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Results 
 
Membrane TNF-α is an inducer of cell death 
To investigate the ability of the membrane versus soluble TNF-α isoforms 
to induce cell death, RAW 264.7 cells, a line derived from murine leukemic 
monocytes/macrophage cells (target), were mixed with 1% paraformaldehyde-
fixed B16F10 melanoma cells (effector) expressing empty vector, ±100 U/ml 
rTNF-α (FxB16cont or FxB16cont+rTNF-α), or fixed mTNF-α-expressing B16F10 
cells (FxB16mTNF) at an target:effector ratio of 1:10. Paraformaldehyde-fixed 
tumor cells were used to eliminate the endogenous sTNF-α (Figure 25A). As 
measured by the MTT dye reduction assay, incubation with FxB16mTNF resulted 
in more than 70±12% cytotoxicity of RAW 264.7 myeloid cells after 48 hours of 
incubation, as compared to RAW 264.7 cells incubated with FxB16cont (Figure 
25B, P<0.05). In contrast FxB16cont+rTNF-α increased RAW 264.7 cell survival 
compared to control. 
To determine the molecular pathway leading to mTNF-α-induced cell 
death, we utilized the highly TNF-α-sensitive L929 fibrosarcoma cell line. As 
shown in Figure 25C, mTNF-α isoform resulted in more than 50% cell death 
compared to L929 cocultured with FXB16cont as determined by MTT reduction 
assay. Cellular toxicity causes membrane damage and results in the release of 
lactate dehydrogenase (LDH) from the cytoplasm and thus LDH in the media can 
also be used to measure cell death. To confirm the results obtained with MTT 
assay, we measured LDH release in L929 cell in the presence of control or 
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mTNF-α-expressing tumor cells.  The mTNF-α isoform increased the level of 
LDH leakage by 12% over control (Figure 25D).   
 
Membrane TNF-α-induced cell death was mediated through either TNFR-1 
or TNFR-2  
 
Membrane TNF-α signal transduction has been linked to a cooperative 
signaling between TNFR-1 and TNFR-2 (Chan et al., 2003; Lazdins et al., 1997). 
Next we sought to determine whether mTNF-α-mediated cell death was 
dependent on a specific TNF receptor. Primary CD11b myeloid cells were 
isolated from wild-type (WT), TNFR-1 knockout (TNFR-1KO), TNFR-2KO or 
TNFR-1 and TNFR-2 double knockout (TNFR-DKO) and cocultured with fixed 
control tumor cells with or without rTNF-α or fixed mTNF-α-expressing tumor 
cells for 48 hours. Cell cytotoxicity was determined by MTT assay. As shown in 
Figure 26, presence of either TNFR-1 or TNFR-2 resulted in increased levels of 
mTNF-α-induced cytotoxicity similar to WT-CD11b (~17% cell death in WT-
CD11b, ~20% in TNFR-1KO-CD11b and TNFR-2KO-CD11b). In contrast, control 
cells treated with rTNF-α improved cell survival in WT- and TNFR-1KO-CD11b 
and resulted only in ~4% cell death in TNFR-2KO-CD11b and ~5% cell death in 
TNFR-DKO-CD11b. Interestingly, mTNF-α-mediated cell cytotoxicity was 
reversed in TNFR-DKO-CD11b cells. These findings suggested that mTNF-α-
induced cell death can be mediated through both TNFR-1 and TNFR-2.   
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Figure 25. Membrane TNF-α isoform effectively induces cell death. (A) 
Schematic diagram of fixed B16F10 cells coculture with L929/RAW264.7. (B) 
RAW cells were cocultured with paraformaldehyde-fixed control (FxB16cont), 
control+rTNF-α (FxB16cont+TNF-α), or mTNFα (FxB16mTNF) for 24 hours. Cell 
death rate was measured by MTT assay. (C) MTT assay showing the cytotoxic 
effects of mTNF-α isoform on L929. (D) LDH assay measuring L929 cells %LDH 
leakage in the presence of control or mTNF-α-expressing fixed B16F10 tumor 
cells. Data show the percentage of LDH leakage into media to total LDH (media 
+ cells). Each sample was assayed in triplicate, with each experiment repeated at 
least 3 times independently. Data are expressed as average ± S.E. P<0.05 and 
P<0.005, 1-way ANOVA with Tukey’s post-test (B), students’s t-test (C and D). 
 
 
 
 73
  
 
 
 
Figure 26. Membrane TNF-α-induced cell death can be mediated through 
both TNFR-1 or TNFR-2. Freshly isolated CD11b myeloid cells from wild type 
mice (WT-CD11b), mice deficient in TNF receptor 1 (TNFR-1KO-CD11b), TNFR-
2KO-CD11b or both receptors (TNFR-DKO-CD11b). Cells were cocultured with 
paraformaldehyde-fixed control (FxB16cont), control in the presence of 100 U/ml 
recombinant TNF-α (FxB16cont+rTNF-α), or mTNF-α (FxB16mTNF) for 24 hours. 
Percentage of cell death was measured by MTT assay. Data present mean 
percentage (bars, mean ± S.E.) of three replicates from 3 independent 
experiments.  
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Membrane TNF-α exerts cell cytotoxicity by increasing intracellular ROS 
production 
 
Induction of cell death by sTNF-α occurs mainly through activation of 
caspases leading to apoptosis. To test whether the mTNF-α isoform exerts its 
cell toxicity in part by activating the caspase pathway, we determined the level of 
cleavage/activation of caspase-3 proteins in L929 cells treated with fixed control 
or mTNF-α-expressing tumor cells.  As presented in Figure 27A, treatment of 
L929 cells with FxB16mTNF did not result in an increased level of active-caspase-
3.  
In the previous chapter we showed that mTNF-α-treated myeloid cells 
exhibit increased intracellular ROS and decreased cell survival. To demonstrate 
an association between intracellular ROS level and cell death in L929 
fibrosarcomas, cells incubated with different TNF-α isoforms were measured 
using CM-H2DCFDA (which quantitatively reacts with oxygen species to produce 
a highly fluorescent dye). L929 cells incubated with FxB16mTNF resulted in a 60% 
increase in CM-H2DCFDA fluorescence, indicating an increase in the level of 
ROS (P>0.05; Figure 27B). Furthermore, incubation of L929 cells with ROS 
scavenger N-acetyl-cysteine (NAC) reduced mTNF-α-mediated ROS level (130% 
of control in FxB16mTNF; 94% of control in FxB16mTNF+NAC; Figure 27C, P<0.5). 
This was followed by 4-fold decrease in LDH release in mTNF-α-treated L929 
cells supplied with NAC (P<0.05; Figure 27D).  
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Figure 27. Membrane TNF-α exerts cell cytotoxicity by increasing 
intracellular ROS production. (A), caspase-3 activity in L929 and RAW 264.7 
cells after incubation with paraformaldehyde-fixed control (FxB16cont) or mTNF-α 
(FxB16mTNF) for 30 minutes.  L929 cells were harvested and total cellular protein 
was analyzed for active caspase-3. (B) ROS production measured by CM-
H2CDFDA intensity in L929 cocultured with fixed control or mTNF-α-expressing 
B16F10. (C and D) Addition of N-acetyl cysteine (2 mM) reduced ROS level (C) 
and decreased LDH leakage into the media (D) in L929 cells. Data are 
represented as percent of CM-H2DCFDA intensity (C) or LDH in media/total LDH 
(D) to L929 cells cocultured with FxB16cont cells with or without NAC. Each 
sample was assayed in triplicate, with each experiment repeated at least 3 times 
independently. Data are expressed as average ± S.E. P<0.05. Students’s t-test.  
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Inhibition of mitochondrial respiratory chain decreased mTNF-α-mediated 
ROS generation 
 
Next we sought to determine the source of ROS in response to mTNF-α in 
L929 cells. There is report of nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase-1 (NOX1) and mitochondria as the two major source of TNF-α 
induced ROS production (Bedard and Krause, 2007; Liu et al., 2002). To do so, 
the NADPH-dependent oxidase and the mitochondrial respiratory chain complex 
II were blocked using DPI (2 μM) and TTFA (0.5 μM) respectively. The NADPH-
dependent oxidase inhibitor DPI did not inhibit the ROS production induced by 
mTNF-α (156.7±8.3% of control in FxB16mTNF and 155.4±14.4% in 
FxB16mTNF+DPI; P<0.05; Figure 28A) and further had no effect on the LDH 
leakage (270% of control in FxB16mTNF and 280% in FxB16mT+DPI; P<0.05; 
Figure 28B). However, addition of TTFA into L929 cells cocultured with mTNF-α-
expressing tumor cells, reduced CM-H2DCFDA oxidation (108% of control) and 
LDH release (10% of control, Figure 28B). These data suggested that 
mitochondria are the source of mTNF-induced ROS generation and cell death.  
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Figure 28. Inhibition of mitochondrial respiratory chain decreases mTNF-α-
mediated ROS generation. (A and B) L929 cell cocultured with mTNF-α-
expressing tumor cells in the absence or presence of NOX inhibitor-DPI (2 μM) 
and mitochondrial complex II inhibitor-TTFA (0.5 μM) for 24 hours. TTFA reduced 
ROS level, shown by reduction of CM-H2DCFDA intensity (A) and LDH leakage 
into media (B). Addition of NOX inhibitor-DPI had no effects on both ROS 
generation of LDH level. Data are represented as % of CM-H2DCFDA intensity 
(A) or LDH in media/total LDH (B) to L929 cells cocultured with control 
expressing tumor cells (FxB16cont) with or without DPI or TTFA. Each sample was 
assayed in triplicate, with each experiment repeated at least 3 times 
independently. Data are expressed as average ± S.E. P<0.05, 1-way ANOVA 
with Tukey’s post-test.  
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Membrane TNF-α-mediated ROS production involves ceramide pathway 
TNFR-mediated mitochondrial ROS generation can be induced through 
RIP-1 kinase activity or through a ceramide-dependent signaling pathway 
initiated by sphingomyelinases (SMases) activity (Figure 29).  To determine the 
specific pathway responsible for activation of mitochondrial ROS production we 
analyzed level of active RIP1 by evaluating its phosphorylation in L929 or RAW 
264.7 in the presence of FxB16cont or FxB16mTNF by immunoblot analysis. As 
shown in Figure 30A, treatment of both cell lines with fixed membrane expressing 
tumor cells, FxB16mTNF, did not increase the level of RIP-1 phosphorylation.  
There is evidence to support the role of ceramide as a second messenger 
of TNF-α activated cells involved in activation of programmed necrosis (Corda et 
al., 2001). Next we evaluated the role of ceramide signaling in TNF-α-induced 
ROS production and survival. Addition of DMAP (1 mM), a CAPK inhibitor, 
reduced mTNF-α-induced ROS by 60% (138±15.6% of control in FxB16mTNF; 
80±2.9% in FxB16mTNF+DMAP; Figure 30B). Percentage of LDH leakage was 
also reduced from 276% in mTNF-α-treated cells to 163% in mTNF-α-treated 
cells supplied with DMAP (P<0.005, Figure 30C). These findings suggested that 
mTNF-α-induced mitochondrial ROS generation requires protein kinase activity 
associated with ceramide. This was further confirmed in RAW 264.7 cell lines. 
Similar to L929 cells, inhibition of CAPK in mTNF-α treated Raw 264.7 cells 
reduced LDH leakage (Figure 30D).    
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Figure 29.  Schematic diagram of TNF-α-activated pathways leading to ROS 
generation. Binding of TNF-α to its receptor activates sphingomyelinases 
(SMase) which convert sphingomyelin (SM) to ceramide. Ceramide activates 
ceramide-activated protein kinase (CAPK) and induces mitochondrial reactive 
oxygen species (ROS) generation. Alternatively, TNFR activation leads to 
autophosphorylation between RIP-1 with RIP-3 result in formation of the 
necrosome. Necrosome induces ROS production via direct effects in the 
mitochondria.  
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Figure 30. Membrane TNF-α-mediated ROS production involves ceramide 
pathway. (A) Level of phospho-RIP1 in L929 or RAW 264.7 cells treated with 
fixed B16F10 control cells (FxB16cont) or B16F10 mTNF-α (FxB16mTNF) cells. 
After 30 min incubation, L929 cells were harvested and total cellular protein was 
analyzed for RIP-1. Inhibition of CAPK reduced mTNF-α-mediated ROS 
generation (B) and LDH release in L929 (C) and LDH release in RAW26.7 (D).  
Data are represented as % of CM-H2DCFDA intensity (B) or LDH in media/total 
LDH (C and D) to cells cocultured with control expressing tumor cells (FxB16cont) 
with or without DMAP. Each sample was assayed in triplicate, with each 
experiment repeated at least 3 times independently. Data are expressed as 
average ± S.E. Student t-test. P<0.05. 
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Discussion 
Previously necrotic cell death has been defined as a sudden, unregulated 
form of cell death which leads to inflammation and tissue damage. However, in 
recent years accumulating evidence suggests that not all form of necrotic cell 
death is accidental but can instead be a programmed event (Morgan et al., 2008; 
Wu et al., 2012). There have been several reports of TNF-α-induced 
programmed necrosis, mainly in the context of the soluble form of TNF-α. 
Importantly, induction of programmed necrosis by sTNF-α typically requires the 
presence of inhibitors of caspases (Robaye et al., 1991; Zhang et al., 2009).  
Here, we present for the first time that the lesser-known membrane form of TNF-
α has the ability to induce programmed necrosis through ROS generation, 
independent of caspase inhibitors. In this study we explored the mechanism of 
mTNF-α-mediated ROS generation and programmed necrosis.  
In our study treatment of mTNF-α-induced L929 cells with mitochondrial 
inhibitor complex II increased ROS reduction and improved survival, suggesting 
a role for mitochondrial complex II in mTNF-α-mediated programmed necrosis. 
The plasma membrane-associated NADPH oxidases (NOX) have been proposed 
as an alternate source of ROS production (Fan et al., 2002; Hordijk, 2006; 
Quinlan et al., 2012). In contrast to what we observed with mitochondrial 
inhibitor, inhibition of NOX failed to inhibit ROS generation and to increase cell 
viability. 
The involvement of the mitochondria in sTNF-α induced ROS production 
has been demonstrated in several studies (Meier et al., 1989; Shoji et al., 1995). 
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The mechanisms by which sTNF-α induces mitochondrial ROS are complex and 
not fully understood. Multiple pathways have been proposed in which activated 
TNFR increases the activity of metabolic enzymes such as glutamine synthase 
(GLUL), glutamate dehydrogenase 1 (GLUD1), and glycogen phosphorylase 
(PYGL) (Zhang et al., 2009).  These metabolic enzymes eventually stimulate the 
TCA cycle and oxidative phosphorylation, which leads to enhanced mitochondrial 
ROS production (Mates et al., 2009). In several studies, inhibition of 
mitochondrial electron transport, using specific inhibitors of mitochondrial 
complex I, II, or III have shown to reverse oxidative stress (Corda et al., 2001; 
Quinlan et al., 2012) .  
Although, RIP1/RIP3 kinases have been shown to orchestrate the 
programmed necrosis pathway activity of sTNF-α, new pathways, such as the 
ceramide pathway, has emerged as alternative mechanism for induction of 
programmed necrosis (Vandenabeele et al., 2010). An enhanced level of 
ceramide has been shown to contribute to depletion of ROS scavenger, 
glutathione (Mari et al., 2004) and increasing mitochondria susceptibility to GD3, 
a ceramide-derived ganglioside. GD3 traffics to the mitochondria and directly 
induces ROS production (Garcia-Ruiz et al., 2002; Garcia-Ruiz et al., 2000). In 
our study mTNF-α-induced ROS and cell death seems to be regulated through 
activity of ceramide since the inhibitor of CAPK, blocked mTNF-α-mediated ROS 
and cell death. Both membrane bound neutral sphingomyelinase (N-SMase) and 
the endosomal acid SMase (A-SMase) shown to be the target of TNFR signal 
transduction in ceramide formation pathway (Cutler and Mattson, 2001; Won and 
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Singh, 2006). TNF-α-induced activation of both A-SMase and N-SMase has been 
implicated in hepatocytes, endothelial (Corda et al., 2001), monocytes 
(Wiegmann et al., 1994) and pre-B cells (Adam et al., 1996).  Whether, mTNF-α 
targets N-SMase or A-SMase remains to be determined.  
Unlike soluble TNF-α which its signal transduction is mediated mainly 
through TNFR-1 (Morgan et al., 2008; Rodriguez-Berriguete et al., 2012), it is 
evident from our study that mTNF-α is efficient in activation of both TNFR-1 and 
TNFR-2. Members of the tumor necrosis factor receptor superfamily (TNFR-1, 
Fas,TRAIL) previously shown to be  capable of inducing cell death (Shen and 
Pervaiz, 2006). These receptors, including TNFR-1 contain a conserved DD in 
the intracellular region that is required for activation of caspases (Gupta, 2002; 
Rangamani and Sirovich, 2007). However induction of cell death by DD-lacking 
TNF receptor superfamily has also been reported.  For instance, TNFR-2 shown 
to trigger cell death in the rhabdomyosarcoma cell line KYM-1 (Grell et al., 1993) 
and the stimulation of CD30 induces cell death in T cell hybridomas (Lee et al., 
1996). It is not yet clear how TNF receptor superfamily members lacking a death 
domain (i.e. TNFR-2) execute their death inducing capability. This effect could be 
FADD-dependent (Depuydt et al., 2005) or could be mediated through 
cooperative activity with other receptors such as Fas/FasL (Teh et al., 2000).  
In conclusion we have demonstrated that mTNF-α can induce cell death 
independent of caspase inhibitors by increasing ROS. This occurs through RIP-
1-independent, ceramide-dependent activation of mitochondrial ROS.  Molecular 
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mechanism, leading to mTNF-α-induced ceramide formation and mitochondrial-
ROS generation, remains to be investigated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER IV 
 
DISSCUSSIONS AND FUTURE DIRECTIONS 
 
Summary 
In this body of work, we showed that membrane and soluble TNF-α 
isoforms have diametrically opposing effects on both tumor growth and myeloid 
content.  Mouse lung and melanoma tumor lines expressing mTNF-α, generated 
smaller tumors devoid of monocytes versus respective control lines or lines 
expressing sTNF-α.  The lack of myeloid cells was due to a direct effect of 
mTNF-α on myeloid survival via induction of cell necrosis by increasing reactive 
oxygen species (ROS) (Figure 31). Next, a novel mechanism by which mTNF-α 
induces programmed cell death was identified (Chapter III). Using a cultured 
RAW 264.7 monocytic cell line and L929 fibroblasts, we found that mTNF-α 
increased ROS-mediated cytotoxicity independent of RIP-1, a serine/threonine 
kinase that serves as a main adaptor protein of sTNF-α induced programmed 
necrosis. Instead, mTNF-α induced ROS generation and cell death through the 
activity of the ceramide pathway as determined by the use of ceramide-activated 
protein kinase (CAPK) inhibitor which prohibited both ROS level and cell death. 
These findings demonstrate that there are significant differences in the 
role of various TNF-α isoforms in tumor progression and that the mTNF-α isoform 
is a more effective inducer of programmed necrosis. This is the first report 
identifying the mTNF-α isoform as a potent activator of programmed necrosis, 
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even in the absence of inhibitors of apoptosis, via ceramide-dependent 
mitochondrial ROS generation. The molecular mechanism by which the two 
different TNF-α isoforms exert distinct biological effects remains elusive. It is 
interesting that although sTNF-α and mTNF-α have similar structures and are 
able to interact with both TNF-α receptors, they exert opposing effects on tumor 
growth and cell survival. This raises questions on the plausible molecular 
mechanisms to account for these differences and how two different isoforms with 
similar structures can elicit such contrasting biological responses.  
In the following sections we will use published literature to establish a link 
between the signaling events leading to programmed necrosis, starting with 
TNFR stimulation which marks the programmed necrosis initiation followed by 
activation of the secondary messenger ceramide and the execution of 
programmed necrosis by increasing mitochondrial ROS.  We will discuss the 
mechanisms by which TNF receptor activation increases ceramide level and 
mitochondrial ROS generation and how different TNF-α isoforms may modulate 
this process differently.  Finally, we will discuss whether activation of 
mitochondrial ROS through ceramide is sufficient to initiate cell death or perhaps 
there are other pathways contributing to these events (Figure 31).  
 
 
 
 
 87
 Figure 31. Schematic overview of tumor-derived soluble and membrane 
TNF-α effects on tumor associated myeloid cells. Soluble TNF-α expression 
by tumor cells results in survival of tumor associated myeloid cells. In contrast, 
membrane TNF-α increases programmed necrosis through increased ceramide-
mediated mitochondrial ROS generation.  
 
 
 
 88
Role of Ceramide in Programmed Necrotic Cell Death 
TNF receptor superfamily is well known for their ability to induce cell 
death. As discussed in chapter I, some of these receptors contain a cytosolic 
death domain which regulates cell death. Programmed necrosis stimulated by 
TFNR-1, Fas and TNF-related apoptosis-inducing ligand receptor-1 and -2 
(TRAIL-R1/2), usually require presence of apoptosis inhibitors or the absence of 
the caspase-8-activating adaptor, FADD.  Once programmed necrosis is initiated, 
multiple factors contribute to the final execution of cell death. One of the most 
studied regulators of necrosis is receptor interacting protein-1 (RIP-1). This 
pathway was discussed in chapter I. Another factor that induces TNF-α-mediated 
necrosis is ceramide, which in our study was identified as the mediator of mTNF-
α-induced mitochondrial ROS and programmed necrosis. Although the 
mechanism by which ceramide induced mitochondrial ROS was not determined, 
some of the necessary molecular events in ceramide-induced mitochondrial ROS 
have been characterized. Interestingly, most of these studies have been done in 
relation to the soluble form of TNF-α and its activation of TNFR-1 and therefore, 
our understanding of mTNF-α mediated ceramide activation and TNFR-2 activity 
is limited.  We hypothesize that the downstream events leading to ceramide-
mediated mitochondrial ROS and cell death are shared by both TNF-α isoforms 
albeit with different initial activation mechanism. In the following section, we will 
discuss the current knowledge of mechanisms by which ceramide contributes to 
programmed cell necrosis and how its activity is linked to TNF-α-mediated ROS 
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production. These pathways could serve as a model for membrane TNF-α-
activated programmed necrosis.   
 
Ceramide as a signaling molecule  
Signaling through the sphingomyelin pathway and the generation of the 
second messenger ceramide is ubiquitous and evolutionarily conserved. Most 
mammalian cells appear capable of signaling through the sphingomyelin pathway 
(Kolesnick and Kronke, 1998). The sphingomyelin pathway has been implicated 
as a major signaling mechanism that modulated the action of a number of 
receptors such as Fas, CD28, CD95, IL-1β and progesterone, causing the 
activation of sphingomyelinases (SMases) (Kolesnick and Kronke, 1998). 
Activated SMases hydrolyze the phosphodiester bond of sphingomyelin to yield 
the second messenger ceramide and phosphorylcholine (Won and Singh, 2006).  
For some of these receptors, ceramide signals immediately after cellular 
activation and hence appears to fulfill the role of a classic second messenger, 
whereas in other instances, ceramide generation is a later response downstream 
of a complex set of interacting signals (Kolesnick and Kronke, 1998). 
 
Ceramide-mediated mitochondrial ROS and programmed necrosis 
Studies have shown that naturally occurring C16 ceramide or addition of 
exogenouse C2-ceramide causes an increase in ROS generation through 
mitochondria (Di Paola et al., 2000; Garcia-Ruiz et al., 1997). Ceramide may 
generate ROS from mitochondria as a consequence of cytochrome c release, an 
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electron carrier of the respiration chain between complexes II and III in 
mitochondria (Cai and Jones, 1998). This was further demonstrated by 
Ghafourifar et al. who showed that C2- and C6-ceramide induce release of 
cytochrome c from isolated mitochondria (Ghafourifar et al., 1999). This led to a 
decrease in mitochondrial oxygen consumption, mitochondrial inner 
transmembrane potential, Ca2+ retention, and finally to mitochondrial dysfunction 
and ROS generation (Ghafourifar et al., 1999). Ceramide was also reported to 
disturb the respiratory chain through direct interaction (Gudz et al., 1997; 
Schulze-Osthoff et al., 1992) as C2- and C6-ceramide treatment induced large 
pores in phospholipid planar membranes (Siskind and Colombini, 2000). 
Dynamic changes in the ceramide content of mitochondrial membranes by 
vesicular transport or local production could possibly regulate mitochondrial 
integrity and ROS generation. 
 
TNFR-1-mediated ceramide generation 
TNFR-1-mediated ceramide signaling is regulated through independent 
activation of two distinct forms of sphingomyelinases (SMases), a membrane-
associated neutral SMase (N-SMase) and an acid SMase (A-SMase), found in 
caveolae and in the endosomal-lysosomal compartment (Liu and Anderson, 
1995; Wiegmann et al., 1994). N-SMase and A-SMase are activated 
independently by a distinct cytoplasmic domain of TNFR-1(Wiegmann et al., 
1994). The domain of TNFR-1 activating the A-SMase pathway corresponds to 
the death domain (DD) (Tartaglia et al., 1993; Wiegmann et al., 1994). This 
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region binds the cytoplasmic protein TRADD which serves as an adapter in 
recruitment of other proteins to the cytoplasmic TNF receptor complex (Hsu et 
al., 1996a; Shu et al., 1996). In contrast, N-SMase activation is mediated by 
neutral sphingomyelinase domain (NSD), which is adjacent to the death domain 
of TNF-R1 (Adam-Klages et al., 1996). The NSD binds FAN (factor associated 
with N-SMase activation) that mediates activation of N-SMase. Ceramide 
generated by N-SMase at the plasma membrane directs the activation of 
ceramide-activated protein kinase (CAPK) (Mathias et al., 1991).  
The described pathways would explain the ceramide-induced 
programmed necrosis in cells expressing DD-containing TNFR-1. However, in 
our study mTNF-α-mediated cell necrosis also occurred in TNFR-1 knockout 
cells, indicating the presence of another distinct pathway independent of the 
death domain region. In the following sections we will propose possible 
mechanisms by which DD-lacking TNFRs can induce cell death. Furthermore, we 
will discuss models by which different TNF-α isoforms can elicit different 
biological responses.  
 
Proposed Models Describing Differential Activity Between Soluble and 
Membrane TNF-α 
 
Receptor/ligand stability 
 
The variation in biological response to the soluble versus the membrane 
form of cytokine receptors activation has been observed in many TNF 
superfamily. The membrane form of molecules such as Fas ligand have been 
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shown to have an opposing role in modulating cell death when compared to their 
soluble form (Date et al., 2003). In a study by Hohlbaum and colleagues it was 
shown that in glaucoma, full-length FasL (i.e. membrane form) accelerates retinal 
ganglion cell death. By contrast, FasL-deficiency or administration of soluble 
FasL has a protective effect (Hohlbaum et al., 2000). TRAIL, which has important 
functions in inducing apoptosis, has been shown to have differential activation 
capacity toward TRAIL-R1 and R2 in a soluble form versus the membrane form 
(Wajant et al., 2001). 
The molecular mechanisms accounting for these differences, remains 
unknown. A model proposed by Grell links mTNF-α isoform differential signaling 
pattern to its ability to form a more stable interaction with TNFRs (Grell et al., 
1995). This model suggests that mTNF-α signaling depends on cell to cell 
contact which creates a juxtaposition of mTNF-α/TNFR, allowing formation of 
ligand-receptor complexes of greater stability with a different quality and quantity 
of the induced cellular response compared to sTNF-α. It is possible that the 
variation in ligand/receptor complex stability, and their half-life, may contribute to 
the different biological responses observed between different isoforms. This 
models remains to be validated.   
 
Differential receptor conformation changes induced by different isoforms 
 
TNF-R1 and TNF-R2 each contain four cysteine-rich repeats in their 
extracellular domains and form elongated shapes which interact with the lateral 
grooves of the trimeric ligand formed between each two of its three protomers 
 93
(Banner et al., 1993; Naismith and Sprang, 1998). Ligand-dependent 
trimerization of the receptors has been known as the key event for signal 
initiation. Ligand binding to the preformed TNFR complex induces conformational 
change and activates the receptor and then acquires signal competence (Wajant 
et al., 2003). Given the diverse events modulated by changes in the spatial 
proximity of cell surface receptors and the trimeric nature of TNF-α, it is possible 
that anchored mTNF-α encourages further modification or spatial arrangement of 
receptors  on adjacent cells which result in induction of different signaling 
pathway. This may lead to differential recruitment of TNFRs adaptor molecules. 
 
Inhibition of TNFR/TNF-α Endocytosis 
Receptor internalization is a widely used mechanism to modulate 
signaling. Binding of hormones and growth factors to their cognate receptors 
typically trigger internalization, leading to transient receptor clearance from the 
surface, followed by either recycling to the membrane or lasting clearance 
through degradation in lysosomes (Bonifacino and Traub, 2003).  Endocytosis 
also is an important mechanism to regulate TNF-α signaling. TNFR/TNF-α 
internalization and lysosomal degradation prohibits TNF signaling pathway and 
subsequent biological responses. Engagement of membrane TNF-α and 
formation of a stable complex may prevent cells from internalizing the TNFRs 
and this may serve as a stress signal which could ultimately induce a necrotic 
cell death. 
 
 94
Clustering of TNFRs and formation of lipid rafts 
The mechanism by which the membrane TNF-α isoform induces cell death 
through DD-lacking TNFR-2 remains unknown. As discussed earlier, the cell 
death inducing property of TNFR-2 has been related to its cooperative nature 
with TNFR-1, through common signal intermediates such as TRAF1 and TRAF2 
(Hsu et al., 1996b; Rothe et al., 1994). Therefore mTNF-α induced cell death 
observed in TNFR-1 knockout cell (chapter III) is indicative of the existence of an 
alternate mechanism that allows DD-lacking receptors to initiate a cell death 
signal.  
It is well known that most TNF receptor superfamily members are able to 
induce cell death; CD40 and CD30 are among these receptors. This is intriguing, 
given the fact that similar to TNFR-2, the cytoplasmic C terminus of CD30 and 40 
lack a death domain homology with the cytotoxic members of the TNFR 
superfamily, such as Fas, TNFR1, and TNF-related apoptosis-inducing ligand 
(TRAIL) receptors (Eliopoulos et al., 2000; Gulbins and Grassme, 2002).  
How these events regulate programmed cell necrosis through ceramide 
could be explained by the formation of lipid rafts.  A variety of receptors including 
CD30, CD40, CD95 and TNFR from the TFNR superfamily, have been shown to 
cluster upon stimulation (Gulbins and Grassme, 2002). Often these clusters are 
formed in cholesterol- and sphingolipid-rich domains of the cell membrane 
referred to as rafts.  Upon activation of these receptors, ASMase is recruited from 
intracellular compartments to the cell surface which results in the release of 
ceramide in rafts, the generation of signaling platforms and the clustering of 
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receptors. Furthermore, rafts often shown to consist of multiple receptor types. It 
is also possible that upon stimulation of TNF receptors by mTNF-α other 
members of TNFR superfamily is recruited into the lipid raft. This has been 
confirmed by showing the localization of TNFR-1 to the CD40 cluster and 
induction of cell death. This process is dependent on the activation of SMase and 
ceramide production (Grassme et al., 2002). Interestingly, disruption of TNFR1 
recruitment to the raft prevented TNF-α-induced cell death in Jurkat cells (Ko et 
al., 1999).  
The intermediates between receptor stimulations and recruitment of 
ASMase are unknown; involvement of factors such as G-protein Ras or Rac 
which have been shown to be activated by TNF receptor superfamily is 
suspected (Brenner et al., 1997). Collectively, these studies provide evidence 
that receptor clustering and rafts are the specific sites of ceramide generation, 
which appears essential in modulation of signaling for some TNF receptor 
superfamily members (Cremesti et al., 2002). It is possible that mTNF-α-
mediated ceramide production is regulated through formation of a cluster of 
receptors in these lipid rich rafts, multiple TNF receptor cluster formation, or 
formation of a receptor cluster with other TNFR superfamily members.  
 
Is mTNF-α-Activated Mitochondrial ROS Sufficient for Induction of 
Programmed Necrosis? 
 
In addition to their role as an inducer of cell death, reactive oxygen 
species are also produced during normal physiological events, and are important 
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in carrying various biological processes (Droge, 2002; Morel and Barouki, 1999; 
Sauer et al., 2001). Therefore, the intracellular levels of ROS are kept tightly 
regulated by numerous ROS defense systems. This raises the question of 
whether mitochondrial ROS generated by mTNF-α- induced ceramide is 
sufficient to disrupt the balance in the redox state of the cell and to initiate 
programmed necrosis or whether there any other factor(s) contributing to the final 
execution of cell death.      
 
Depletion of ROS scavengers  
ROS generation alone is not the source of oxidative stress, but cellular 
stress is ultimately driven by an imbalance in ROS production and detoxification. 
One way to disrupt the ROS homeostasis of the cells is to allow the accumulation 
of ROS by eliminating the scavangers present in the cell. This causes  the 
imbalance of free radicals and their scavengers, increasing the level of ROS and 
inducing DNA (Marnett, 2000), protein (Berlett and Stadtman, 1997) and lipid 
(Noguchi et al., 2002) damage. Interestingly, an enhanced level of ceramide has 
been shown to contribute to depletion of the ROS scavenger, glutathione (Mari et 
al., 2004) and increasing mitochondria susceptibility to GD3, a ceramide-derived 
ganglioside. GD3 trafficking to the mitochondria directly induces ROS production 
(Garcia-Ruiz et al., 2002; Garcia-Ruiz et al., 2000). It would be interesting to see 
whether the availability of antioxidant enzymes in mTNF-α-treated cells are 
affected. This could be evaluated by assessing the level of different scavengers 
in mTNF-α treated cells. 
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Sustained JNK activation 
A significant increase in ROS level is necessary to disturb the intracellular 
ROS balance and initiate programmed necrosis. It is plausible that in addition to 
direct mTNF-α-activation of mitochondria, activation of other ROS inducing 
pathways also contribute to this event. It has been well established that ROS 
plays a critical role in TNF-α-mediated c-Jun NH2-terminal kinase (JNK, known 
as stress-activated protein kinases) activation and TNF-α induced necrotic cell 
death. Elevated levels of ROS immediate prolonged JNK activation and TNF-α-
induced ROS, cause oxidation and inhibition of JNK-inactivating phosphatases 
by converting their catalytic cysteine to sulfenic acid. This results in sustained 
JNK activation; activated JNK further promotes ROS production from 
mitochondria, forming a positive feedback loop, enhancing necrosis (Shen and 
Pervaiz, 2006; Wu et al., 2012). It is possible that mTNF-α induced ROS and 
programmed cell necrosis is also mediated in part by further activation of JNK 
and related genes further increasing ROS levels (Figure 32).   
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Figure 32. Proposed mechanism of mTNF-α activated ceramide pathway 
and mitochondrial ROS generation. Membrane anchored TNF-α creates a 
more stable contact with TNFR1/2 with a longer half-life.  This allows the 
formation of higher-order receptor complexes (receptor clustering). These 
clusters of receptors are formed in lipid rafts abundant in sphingomyelin which 
are the precursor of ceramide. This activates ASM and triggers a translocation of 
the enzyme onto the sphinomyelin rich lipid rafts leading to an increase in 
intracellular ceramide level. Ceramide will decrease mitochondrial membrane 
integrity and reactive oxygen species (ROS) leakage which could increase DNA, 
protein, and organelle damage or further increase JNK activity and in return 
create a positive feedback and further increasing mitochondrial ROS.   
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Significance 
For many years interactions between tumor-infiltrating myeloid and tumor 
cells have been of great interest since they both promote and inhibit tumor 
formation, growth and progression. This study further highlights the importance of 
tumor derived cytokines and their contribution to malignant growth by modulating 
inflammatory cells in cancer.  
In chapter II it was shown that human NSCLC tumor cell express both 
soluble and membrane TNF-α at varying levels. Analysis of Human none-small-
cells lung carcinomas (NSCLCs) microarray database showed that TNF-α and 
TACE expression patterns favoring mTNF-α were predictive of improved lung 
cancer survival. These findings suggest that the bioavailability of each isoform 
may distinctly regulate tumor progression and analysis of TNF-α gene expression 
and the level of soluble and membrane TNF-α could potentially be used as a 
prognostic/therapeutic tool.  This study is the first to suggest that TNF-α isoform 
analysis should be applied to identify candidates for which anti-TNF-α agents are 
likely to be beneficial vs. detrimental. These finding further allows us to determine 
the utility of novel cancer treatments that inhibit TNF-α dependent tumor growth 
such as development of drugs that inhibit cleavage of membrane TNF-α as an 
alternate cancer treatment.   
Despite the large body of published studies on the role of this important 
cytokine in cancer, the molecular and physiological context, necessary for 
optimal targeting of TNF in malignant disease, is still not clear. This has posed a 
challenge in using many of the FDA approved anti-TNF in effective cancer 
 100
therapy.  Our work provides new insights on this paradox and on how we may 
rationally move TNF-α-targeted therapy forward. This information is of great 
interest as anti-TNF-α agents have recently been used in phase I/II clinical trials 
without significant benefit.  
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